Spaces:
Sleeping
Sleeping
File size: 182,331 Bytes
1a3b3aa |
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 1053 1054 1055 1056 1057 1058 1059 1060 1061 1062 1063 1064 1065 1066 1067 1068 1069 1070 1071 1072 1073 1074 1075 1076 1077 1078 1079 1080 1081 1082 1083 1084 1085 1086 1087 1088 1089 1090 1091 1092 1093 1094 1095 1096 1097 1098 1099 1100 1101 1102 1103 1104 1105 1106 1107 1108 1109 1110 1111 1112 1113 1114 1115 1116 1117 1118 1119 1120 1121 1122 1123 1124 1125 1126 1127 1128 1129 1130 1131 1132 1133 1134 1135 1136 1137 1138 1139 1140 1141 1142 1143 1144 1145 1146 1147 1148 1149 1150 1151 1152 1153 1154 1155 1156 1157 1158 1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 1170 1171 1172 1173 1174 1175 1176 1177 1178 1179 1180 1181 1182 1183 1184 1185 1186 1187 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 1205 1206 1207 1208 1209 1210 1211 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 1223 1224 1225 1226 1227 1228 1229 1230 1231 1232 1233 1234 1235 1236 1237 1238 1239 1240 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250 1251 1252 1253 1254 1255 1256 1257 1258 1259 1260 1261 1262 1263 1264 1265 1266 1267 1268 1269 1270 1271 1272 1273 1274 1275 1276 1277 1278 1279 1280 1281 1282 1283 1284 1285 1286 1287 1288 1289 1290 1291 1292 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302 1303 1304 1305 1306 1307 1308 1309 1310 1311 1312 1313 1314 1315 1316 1317 1318 1319 1320 1321 1322 1323 1324 1325 1326 1327 1328 1329 1330 1331 1332 1333 1334 1335 1336 1337 1338 1339 1340 1341 1342 1343 1344 1345 1346 1347 1348 1349 1350 1351 1352 1353 1354 1355 1356 1357 1358 1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370 1371 1372 1373 1374 1375 1376 1377 1378 1379 1380 1381 1382 1383 1384 1385 1386 1387 1388 1389 1390 1391 1392 1393 1394 1395 1396 1397 1398 1399 1400 1401 1402 1403 1404 1405 1406 1407 1408 1409 1410 1411 1412 1413 1414 1415 1416 1417 1418 1419 1420 1421 1422 1423 1424 1425 1426 1427 1428 1429 1430 1431 1432 1433 1434 1435 1436 1437 1438 1439 1440 1441 1442 1443 1444 1445 1446 1447 1448 1449 1450 1451 1452 1453 1454 1455 1456 1457 1458 1459 1460 1461 1462 1463 1464 1465 1466 1467 1468 1469 1470 1471 1472 1473 1474 1475 1476 1477 1478 1479 1480 1481 1482 1483 1484 1485 1486 1487 1488 1489 1490 1491 1492 1493 1494 1495 1496 1497 1498 1499 1500 1501 1502 1503 1504 1505 1506 1507 1508 1509 1510 1511 1512 1513 1514 1515 1516 1517 1518 1519 1520 1521 1522 1523 1524 1525 1526 1527 1528 1529 1530 1531 1532 1533 1534 1535 1536 1537 1538 1539 1540 1541 1542 1543 1544 1545 1546 1547 1548 1549 1550 1551 1552 1553 1554 1555 1556 1557 1558 1559 1560 1561 1562 1563 1564 1565 1566 1567 1568 1569 1570 1571 1572 1573 1574 1575 1576 1577 1578 1579 1580 1581 1582 1583 1584 1585 1586 1587 1588 1589 1590 1591 1592 1593 1594 1595 1596 1597 1598 1599 1600 1601 1602 1603 1604 1605 1606 1607 1608 1609 1610 1611 1612 1613 1614 1615 1616 1617 1618 1619 1620 1621 1622 1623 1624 1625 1626 1627 1628 1629 1630 1631 1632 1633 1634 1635 1636 1637 1638 1639 1640 1641 1642 1643 1644 1645 1646 1647 1648 1649 1650 1651 1652 1653 1654 1655 1656 1657 1658 1659 1660 1661 1662 1663 1664 1665 1666 1667 1668 1669 1670 1671 1672 1673 1674 1675 1676 1677 1678 1679 1680 1681 1682 1683 1684 1685 1686 1687 1688 1689 1690 1691 1692 1693 1694 1695 1696 1697 1698 1699 1700 1701 1702 1703 1704 1705 1706 1707 1708 1709 1710 1711 1712 1713 1714 1715 1716 1717 1718 1719 1720 1721 1722 1723 1724 1725 1726 1727 1728 1729 1730 1731 1732 1733 1734 1735 1736 1737 1738 1739 1740 1741 1742 1743 1744 1745 1746 1747 1748 1749 1750 1751 1752 1753 1754 1755 1756 1757 1758 1759 1760 1761 1762 1763 1764 1765 1766 1767 1768 1769 1770 1771 1772 1773 1774 1775 1776 1777 1778 1779 1780 1781 1782 1783 1784 1785 1786 1787 1788 1789 1790 1791 1792 1793 1794 1795 1796 1797 1798 1799 1800 1801 1802 1803 1804 1805 1806 1807 1808 1809 1810 1811 1812 1813 1814 1815 1816 1817 1818 1819 1820 1821 1822 1823 1824 1825 1826 1827 1828 1829 1830 1831 1832 1833 1834 1835 1836 1837 1838 1839 1840 1841 1842 1843 1844 1845 1846 1847 1848 1849 1850 1851 1852 1853 1854 1855 1856 1857 1858 1859 1860 1861 1862 1863 1864 1865 1866 1867 1868 1869 1870 1871 1872 1873 1874 1875 1876 1877 1878 1879 1880 1881 1882 1883 1884 1885 1886 1887 1888 1889 1890 1891 1892 1893 1894 1895 1896 1897 1898 1899 1900 1901 1902 1903 1904 1905 1906 1907 1908 1909 1910 1911 1912 1913 1914 1915 1916 1917 1918 1919 1920 1921 1922 1923 1924 1925 1926 1927 1928 1929 1930 1931 1932 1933 1934 1935 1936 1937 1938 1939 1940 1941 1942 1943 1944 1945 1946 1947 1948 1949 1950 1951 1952 1953 1954 1955 1956 1957 1958 1959 1960 1961 1962 1963 1964 1965 1966 1967 1968 1969 1970 1971 1972 1973 1974 1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 2043 2044 2045 2046 2047 2048 2049 2050 2051 2052 2053 2054 2055 2056 2057 2058 2059 2060 2061 2062 2063 2064 2065 2066 2067 2068 2069 2070 2071 2072 2073 2074 2075 2076 2077 2078 2079 2080 2081 2082 2083 2084 2085 2086 2087 2088 2089 2090 2091 2092 2093 2094 2095 2096 2097 2098 2099 2100 2101 2102 2103 2104 2105 2106 2107 2108 2109 2110 2111 2112 2113 2114 2115 2116 2117 2118 2119 2120 2121 2122 2123 2124 2125 2126 2127 2128 2129 2130 2131 2132 2133 2134 2135 2136 2137 2138 2139 2140 2141 2142 2143 2144 2145 2146 2147 2148 2149 2150 2151 2152 2153 2154 2155 2156 2157 2158 2159 2160 2161 2162 2163 2164 2165 2166 2167 2168 2169 2170 2171 2172 2173 2174 2175 2176 2177 2178 2179 2180 2181 2182 2183 2184 2185 2186 2187 2188 2189 2190 2191 2192 2193 2194 2195 2196 2197 2198 2199 2200 2201 2202 2203 2204 2205 2206 2207 2208 2209 2210 2211 2212 2213 2214 2215 2216 2217 2218 2219 2220 2221 2222 2223 2224 2225 2226 2227 2228 2229 2230 2231 2232 2233 2234 2235 2236 2237 2238 2239 2240 2241 2242 2243 2244 2245 2246 2247 2248 2249 2250 2251 2252 2253 2254 2255 2256 2257 2258 2259 2260 2261 2262 2263 2264 2265 2266 2267 2268 2269 2270 2271 2272 2273 2274 2275 2276 2277 2278 2279 2280 2281 2282 2283 2284 2285 2286 2287 2288 2289 2290 2291 2292 2293 2294 2295 2296 2297 2298 2299 2300 2301 2302 2303 2304 2305 2306 2307 2308 2309 2310 2311 2312 2313 2314 2315 2316 2317 2318 2319 2320 2321 2322 2323 2324 2325 2326 2327 2328 2329 2330 2331 2332 2333 2334 2335 2336 2337 2338 2339 2340 2341 2342 2343 2344 2345 2346 2347 2348 2349 2350 2351 2352 2353 2354 2355 2356 2357 2358 2359 2360 2361 2362 2363 2364 2365 2366 2367 2368 2369 2370 2371 2372 2373 2374 2375 2376 2377 2378 2379 2380 2381 2382 2383 2384 2385 2386 2387 2388 2389 2390 2391 2392 2393 2394 2395 2396 2397 2398 2399 2400 2401 2402 2403 2404 2405 2406 2407 2408 2409 2410 2411 2412 2413 2414 2415 2416 2417 2418 2419 2420 2421 2422 2423 2424 2425 2426 2427 2428 2429 2430 2431 2432 2433 2434 2435 2436 2437 2438 2439 2440 2441 2442 2443 2444 2445 2446 2447 2448 2449 2450 2451 2452 2453 2454 2455 2456 2457 2458 2459 2460 2461 2462 2463 2464 2465 2466 2467 2468 2469 2470 2471 2472 2473 2474 2475 2476 2477 2478 2479 2480 2481 2482 2483 2484 2485 2486 2487 2488 2489 2490 2491 2492 2493 2494 2495 2496 2497 2498 2499 2500 2501 2502 2503 2504 2505 2506 2507 2508 2509 2510 2511 2512 2513 2514 2515 2516 2517 2518 2519 2520 2521 2522 2523 2524 2525 2526 2527 2528 2529 2530 2531 2532 2533 2534 2535 2536 2537 2538 2539 2540 2541 2542 2543 2544 2545 2546 2547 2548 2549 2550 2551 2552 2553 2554 2555 2556 2557 2558 2559 2560 2561 2562 2563 2564 2565 2566 2567 2568 2569 2570 2571 2572 2573 2574 2575 2576 2577 2578 2579 2580 2581 2582 2583 2584 2585 2586 2587 2588 2589 2590 2591 2592 2593 2594 2595 2596 2597 2598 2599 2600 2601 2602 2603 2604 2605 2606 2607 2608 2609 2610 2611 2612 2613 2614 2615 2616 2617 2618 2619 2620 2621 2622 2623 2624 2625 2626 2627 2628 2629 2630 2631 2632 2633 2634 2635 2636 2637 2638 2639 2640 2641 2642 2643 2644 2645 2646 2647 2648 2649 2650 2651 2652 2653 2654 2655 2656 2657 2658 2659 2660 2661 2662 2663 2664 2665 2666 2667 2668 2669 2670 2671 2672 2673 2674 2675 2676 2677 2678 2679 2680 2681 2682 2683 2684 2685 2686 2687 2688 2689 2690 2691 2692 2693 2694 2695 2696 2697 2698 2699 2700 2701 2702 2703 2704 2705 2706 2707 2708 2709 2710 2711 2712 2713 2714 2715 2716 2717 2718 2719 2720 2721 2722 2723 2724 2725 2726 2727 2728 2729 2730 2731 2732 2733 2734 2735 2736 2737 2738 2739 2740 2741 2742 2743 2744 2745 2746 2747 2748 2749 2750 2751 2752 2753 2754 2755 2756 2757 2758 2759 2760 2761 2762 2763 2764 2765 2766 2767 2768 2769 2770 2771 2772 2773 2774 2775 2776 2777 2778 2779 2780 2781 2782 2783 2784 2785 2786 2787 2788 2789 2790 2791 2792 2793 2794 2795 2796 2797 2798 2799 2800 2801 2802 2803 2804 2805 2806 2807 2808 2809 2810 2811 2812 2813 2814 2815 2816 2817 2818 2819 2820 2821 2822 2823 2824 2825 2826 2827 2828 2829 2830 2831 2832 2833 2834 2835 2836 2837 2838 2839 2840 2841 2842 2843 2844 2845 2846 2847 2848 2849 2850 2851 2852 2853 2854 2855 2856 2857 2858 2859 2860 2861 2862 2863 2864 2865 2866 2867 2868 2869 2870 2871 2872 2873 2874 2875 2876 2877 2878 2879 2880 2881 2882 2883 2884 2885 2886 2887 2888 2889 2890 2891 2892 2893 2894 2895 2896 2897 2898 2899 2900 2901 2902 2903 2904 2905 2906 2907 2908 2909 2910 2911 2912 2913 2914 2915 2916 2917 2918 2919 2920 2921 2922 2923 2924 2925 2926 2927 2928 2929 2930 2931 2932 2933 2934 2935 2936 2937 2938 2939 2940 2941 2942 2943 2944 2945 2946 2947 2948 2949 2950 2951 2952 2953 2954 2955 2956 2957 2958 2959 2960 2961 2962 2963 2964 2965 2966 2967 2968 2969 2970 2971 2972 2973 2974 2975 2976 2977 2978 2979 2980 2981 2982 2983 2984 |
<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
<PMID Version="1">36473651</PMID>
<DateCompleted>
<Year>2022</Year>
<Month>12</Month>
<Day>15</Day>
</DateCompleted>
<DateRevised>
<Year>2024</Year>
<Month>06</Month>
<Day>05</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">1469-493X</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>12</Volume>
<Issue>12</Issue>
<PubDate>
<Year>2022</Year>
<Month>Dec</Month>
<Day>07</Day>
</PubDate>
</JournalIssue>
<Title>The Cochrane database of systematic reviews</Title>
<ISOAbbreviation>Cochrane Database Syst Rev</ISOAbbreviation>
</Journal>
<ArticleTitle>Efficacy and safety of COVID-19 vaccines.</ArticleTitle>
<Pagination>
<StartPage>CD015477</StartPage>
<MedlinePgn>CD015477</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">CD015477</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/14651858.CD015477</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND">Different forms of vaccines have been developed
to prevent the SARS-CoV-2 virus and subsequent COVID-19 disease. Several are
in widespread use globally.  OBJECTIVES: To assess the efficacy and
safety of COVID-19 vaccines (as a full primary vaccination series or a
booster dose) against SARS-CoV-2.</AbstractText>
<AbstractText Label="SEARCH METHODS">We searched the Cochrane COVID-19 Study
Register and the COVID-19 L·OVE platform (last search date 5 November
2021). We also searched the WHO International Clinical Trials Registry
Platform, regulatory agency websites, and Retraction Watch.</AbstractText>
<AbstractText Label="SELECTION CRITERIA">We included randomized controlled
trials (RCTs) comparing COVID-19 vaccines to placebo, no vaccine, other
active vaccines, or other vaccine schedules.</AbstractText>
<AbstractText Label="DATA COLLECTION AND ANALYSIS">We used standard Cochrane
methods. We used GRADE to assess the certainty of evidence for all except
immunogenicity outcomes.  We synthesized data for each vaccine
separately and presented summary effect estimates with 95% confidence
intervals (CIs).  MAIN RESULTS: We included and analyzed 41 RCTs
assessing 12 different vaccines, including homologous and heterologous
vaccine schedules and the effect of booster doses. Thirty-two RCTs were
multicentre and five were multinational. The sample sizes of RCTs were 60 to
44,325 participants. Participants were aged: 18 years or older in 36 RCTs;
12 years or older in one RCT; 12 to 17 years in two RCTs; and three to 17
years in two RCTs. Twenty-nine RCTs provided results for individuals aged
over 60 years, and three RCTs included immunocompromized patients. No trials
included pregnant women. Sixteen RCTs had two-month follow-up or less, 20
RCTs had two to six months, and five RCTs had greater than six to 12 months
or less. Eighteen reports were based on preplanned interim analyses. Overall
risk of bias was low for all outcomes in eight RCTs, while 33 had concerns
for at least one outcome. We identified 343 registered RCTs with results not
yet available.  This abstract reports results for the critical outcomes
of confirmed symptomatic COVID-19, severe and critical COVID-19, and serious
adverse events only for the 10 WHO-approved vaccines. For remaining outcomes
and vaccines, see main text. The evidence for mortality was generally sparse
and of low or very low certainty for all WHO-approved vaccines, except
AD26.COV2.S (Janssen), which probably reduces the risk of all-cause
mortality (risk ratio (RR) 0.25, 95% CI 0.09 to 0.67; 1 RCT, 43,783
participants; high-certainty evidence). Confirmed symptomatic COVID-19
High-certainty evidence found that BNT162b2 (BioNtech/Fosun Pharma/Pfizer),
mRNA-1273 (ModernaTx), ChAdOx1 (Oxford/AstraZeneca), Ad26.COV2.S, BBIBP-CorV
(Sinopharm-Beijing), and BBV152 (Bharat Biotect) reduce the incidence of
symptomatic COVID-19 compared to placebo (vaccine efficacy (VE): BNT162b2:
97.84%, 95% CI 44.25% to 99.92%; 2 RCTs, 44,077 participants; mRNA-1273:
93.20%, 95% CI 91.06% to 94.83%; 2 RCTs, 31,632 participants; ChAdOx1:
70.23%, 95% CI 62.10% to 76.62%; 2 RCTs, 43,390 participants; Ad26.COV2.S:
66.90%, 95% CI 59.10% to 73.40%; 1 RCT, 39,058 participants; BBIBP-CorV:
78.10%, 95% CI 64.80% to 86.30%; 1 RCT, 25,463 participants; BBV152: 77.80%,
95% CI 65.20% to 86.40%; 1 RCT, 16,973 participants). Moderate-certainty
evidence found that NVX-CoV2373 (Novavax) probably reduces the incidence of
symptomatic COVID-19 compared to placebo (VE 82.91%, 95% CI 50.49% to
94.10%; 3 RCTs, 42,175 participants). There is low-certainty evidence for
CoronaVac (Sinovac) for this outcome (VE 69.81%, 95% CI 12.27% to 89.61%; 2
RCTs, 19,852 participants). Severe or critical COVID-19 High-certainty
evidence found that BNT162b2, mRNA-1273, Ad26.COV2.S, and BBV152 result in a
large reduction in incidence of severe or critical disease due to COVID-19
compared to placebo (VE: BNT162b2: 95.70%, 95% CI 73.90% to 99.90%; 1 RCT,
46,077 participants; mRNA-1273: 98.20%, 95% CI 92.80% to 99.60%; 1 RCT,
28,451 participants; AD26.COV2.S: 76.30%, 95% CI 57.90% to 87.50%; 1 RCT,
39,058 participants; BBV152: 93.40%, 95% CI 57.10% to 99.80%; 1 RCT, 16,976
participants). Moderate-certainty evidence found that NVX-CoV2373 probably
reduces the incidence of severe or critical COVID-19 (VE 100.00%, 95% CI
86.99% to 100.00%; 1 RCT, 25,452 participants). Two trials reported high
efficacy of CoronaVac for severe or critical disease with wide CIs, but
these results could not be pooled. Serious adverse events (SAEs) mRNA-1273,
ChAdOx1 (Oxford-AstraZeneca)/SII-ChAdOx1 (Serum Institute of India),
Ad26.COV2.S, and BBV152 probably result in little or no difference in SAEs
compared to placebo (RR: mRNA-1273: 0.92, 95% CI 0.78 to 1.08; 2 RCTs,
34,072 participants; ChAdOx1/SII-ChAdOx1: 0.88, 95% CI 0.72 to 1.07; 7 RCTs,
58,182 participants; Ad26.COV2.S: 0.92, 95% CI 0.69 to 1.22; 1 RCT, 43,783
participants); BBV152: 0.65, 95% CI 0.43 to 0.97; 1 RCT, 25,928
participants). In each of these, the likely absolute difference in effects
was fewer than 5/1000 participants. Evidence for SAEs is uncertain for
BNT162b2, CoronaVac, BBIBP-CorV, and NVX-CoV2373 compared to placebo (RR:
BNT162b2: 1.30, 95% CI 0.55 to 3.07; 2 RCTs, 46,107 participants; CoronaVac:
0.97, 95% CI 0.62 to 1.51; 4 RCTs, 23,139 participants; BBIBP-CorV: 0.76,
95% CI 0.54 to 1.06; 1 RCT, 26,924 participants; NVX-CoV2373: 0.92, 95% CI
0.74 to 1.14; 4 RCTs, 38,802 participants). For the evaluation of
heterologous schedules, booster doses, and efficacy against variants of
concern, see main text of review.</AbstractText>
<AbstractText Label="AUTHORS' CONCLUSIONS">Compared to placebo, most vaccines
reduce, or likely reduce, the proportion of participants with confirmed
symptomatic COVID-19, and for some, there is high-certainty evidence that
they reduce severe or critical disease. There is probably little or no
difference between most vaccines and placebo for serious adverse events.
Over 300 registered RCTs are evaluating the efficacy of COVID-19 vaccines,
and this review is updated regularly on the COVID-NMA platform
(covid-nma.com). Implications for practice Due to the trial exclusions,
these results cannot be generalized to pregnant women, individuals with a
history of SARS-CoV-2 infection, or immunocompromized people. Most trials
had a short follow-up and were conducted before the emergence of variants of
concern. Implications for research Future research should evaluate the
long-term effect of vaccines, compare different vaccines and vaccine
schedules, assess vaccine efficacy and safety in specific populations, and
include outcomes such as preventing long COVID-19. Ongoing evaluation of
vaccine efficacy and effectiveness against emerging variants of concern is
also vital.</AbstractText>
<CopyrightInformation>Copyright © 2022 The Authors. Cochrane Database of
Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Graña</LastName>
<ForeName>Carolina</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Cochrane France, Paris, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>Centre of Research in Epidemiology and Statistics (CRESS),
INSERM, INRAE, Université de Paris, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ghosn</LastName>
<ForeName>Lina</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Cochrane France, Paris, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>Centre of Research in Epidemiology and Statistics (CRESS),
INSERM, INRAE, Université de Paris, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Evrenoglou</LastName>
<ForeName>Theodoros</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Centre of Research in Epidemiology and Statistics (CRESS),
INSERM, INRAE, Université de Paris, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jarde</LastName>
<ForeName>Alexander</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Cochrane France, Paris, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>Centre of Research in Epidemiology and Statistics (CRESS),
INSERM, INRAE, Université de Paris, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Minozzi</LastName>
<ForeName>Silvia</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Cochrane Review Group on Drugs and Alcohol, Rome, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bergman</LastName>
<ForeName>Hanna</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Cochrane Response, Cochrane, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Buckley</LastName>
<ForeName>Brian S</ForeName>
<Initials>BS</Initials>
<AffiliationInfo>
<Affiliation>Cochrane Response, Cochrane, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Probyn</LastName>
<ForeName>Katrin</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Cochrane Response, Cochrane, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Villanueva</LastName>
<ForeName>Gemma</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Cochrane Response, Cochrane, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Henschke</LastName>
<ForeName>Nicholas</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Cochrane Response, Cochrane, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bonnet</LastName>
<ForeName>Hillary</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Cochrane France, Paris, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>Centre of Research in Epidemiology and Statistics (CRESS),
INSERM, INRAE, Université de Paris, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Assi</LastName>
<ForeName>Rouba</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Cochrane France, Paris, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>Centre of Research in Epidemiology and Statistics (CRESS),
INSERM, INRAE, Université de Paris, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Menon</LastName>
<ForeName>Sonia</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Cochrane France, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Marti</LastName>
<ForeName>Melanie</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Immunization, Vaccines and Biologicals, World
Health Organization, Geneva, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Devane</LastName>
<ForeName>Declan</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Evidence Synthesis Ireland, Cochrane Ireland and HRB-Trials
Methodology Research Network, National University of Ireland,
Galway, Ireland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mallon</LastName>
<ForeName>Patrick</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>UCD Centre for Experimental Pathogen Host Research and UCD
School of Medicine, University College Dublin, Dublin, Ireland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lelievre</LastName>
<ForeName>Jean-Daniel</ForeName>
<Initials>JD</Initials>
<AffiliationInfo>
<Affiliation>Department of Clinical Immunology and Infectious Diseases,
Henri Mondor Hospital, Vaccine Research Institute, Université
Paris Est Créteil, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Askie</LastName>
<ForeName>Lisa M</ForeName>
<Initials>LM</Initials>
<AffiliationInfo>
<Affiliation>Quality Assurance Norms and Standards Department, World
Health Organization, Geneva, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kredo</LastName>
<ForeName>Tamara</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Cochrane South Africa, South African Medical Research
Council, Cape Town, South Africa.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ferrand</LastName>
<ForeName>Gabriel</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Cochrane France, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Davidson</LastName>
<ForeName>Mauricia</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Cochrane France, Paris, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>Centre of Research in Epidemiology and Statistics (CRESS),
INSERM, INRAE, Université de Paris, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Riveros</LastName>
<ForeName>Carolina</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Cochrane France, Paris, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>Centre of Research in Epidemiology and Statistics (CRESS),
INSERM, INRAE, Université de Paris, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tovey</LastName>
<ForeName>David</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Cochrane France, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Meerpohl</LastName>
<ForeName>Joerg J</ForeName>
<Initials>JJ</Initials>
<AffiliationInfo>
<Affiliation>Institute for Evidence in Medicine, Medical Center &
Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>Cochrane Germany, Cochrane Germany Foundation, Freiburg,
Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Grasselli</LastName>
<ForeName>Giacomo</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Department of Anesthesia, Intensive Care and Emergency,
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico,
Department of Pathophysiology and Transplantation, University of
Milan, Milan, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rada</LastName>
<ForeName>Gabriel</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Epistemonikos Foundation, Santiago, Chile.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>UC Evidence Center, Cochrane Chile Associated Center,
Pontificia Universidad Católica de Chile, Santiago, Chile.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hróbjartsson</LastName>
<ForeName>Asbjørn</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Centre for Evidence Based Medicine Odense (CEBMO) and
Cochrane Denmark, University of Southern Denmark, Odense, Denmark.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>Open Patient data Explorative Network (OPEN), Odense
University Hospital, Odense, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ravaud</LastName>
<ForeName>Philippe</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Cochrane France, Paris, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>Centre of Research in Epidemiology and Statistics (CRESS),
INSERM, INRAE, Université de Paris, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chaimani</LastName>
<ForeName>Anna</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Cochrane France, Paris, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>Centre of Research in Epidemiology and Statistics (CRESS),
INSERM, INRAE, Université de Paris, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Boutron</LastName>
<ForeName>Isabelle</ForeName>
<Initials>I</Initials>
<AffiliationInfo>
<Affiliation>Cochrane France, Paris, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>Centre of Research in Epidemiology and Statistics (CRESS),
INSERM, INRAE, Université de Paris, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>001</GrantID>
<Acronym>WHO_</Acronym>
<Agency>World Health Organization</Agency>
<Country>International</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
<PublicationType UI="D000078182">Systematic Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2022</Year>
<Month>12</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Cochrane Database Syst Rev</MedlineTA>
<NlmUniqueID>100909747</NlmUniqueID>
<ISSNLinking>1361-6137</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C000722216">sinovac COVID-19 vaccine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C000722768">BIBP COVID-19 vaccine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>76JZE5DSN6</RegistryNumber>
<NameOfSubstance UI="C000722386">BBV152 COVID-19 vaccine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EPK39PL4R4</RegistryNumber>
<NameOfSubstance UI="D000090983">2019-nCoV Vaccine mRNA-1273</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000090983" MajorTopicYN="Y">2019-nCoV Vaccine mRNA-1273</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<CoiStatement>Carolina Graña: none known. Lina Ghosn: none known. Theodoros
Evrenoglou: none known. Alexander Jarde: none known. Silvia Minozzi: no relevant
interests; Joint Co‐ordinating Editor and Method editor of the Drugs and
Alcohol Group. Hanna Bergman: Cochrane Response – consultant; WHO –
grant/contract (Cochrane Response was commissioned by the WHO to perform review
tasks that contribute to this publication). . Brian Buckley: none known. .
Katrin Probyn: Cochrane Response – consultant; WHO – consultant
(Cochrane Response was commissioned to perform review tasks that contribute to this
publication). . Gemma Villanueva: Cochrane Response – employment
(Cochrane Response has been commissioned by WHO to perform parts of this systematic
review). . Nicholas Henschke: Cochrane Response – consultant; WHO
– consultant (Cochrane Response was commissioned by the WHO to perform review
tasks that contributed to this publication). . Hillary Bonnet: none known.
Rouba Assi: none known. Sonia Menon: P95 – consultant. Melanie Marti: no
relevant interests; Medical Officer at WHO. Declan Devane: Health Research Board
(HRB) – grant/contract; registered nurse and registered midwife but no longer
in clinical practice; Editor, Cochrane Pregnancy and Childbirth Group. Patrick
Mallon: AstraZeneca – Advisory Board; spoken of vaccine effectiveness to
media (print, online, and live); works as a consultant in a hospital that provides
vaccinations; employed by St Vincent's University Hospital. Jean‐Daniel
Lelievre: no relevant interests; published numerous interviews in the national press
on the subject of COVID vaccination; Head of the Department of Infectious Diseases
and Clinical Immunology CHU Henri Mondor APHP, Créteil; WHO (IVRI‐AC):
expert Vaccelarate (European project on COVID19 Vaccine): head of WP; involved with
COVICOMPARE P et M Studies (APHP, INSERM) (public fundings). . Lisa Askie: no
relevant interests; Co‐convenor, Cochrane Prospective Meta‐analysis
Methods Group. Tamara Kredo: no relevant interests; Medical Officer in an Infectious
Diseases Clinic at Tygerberg Hospital, Stellenbosch University. Gabriel Ferrand:
none known. Mauricia Davidson: none known. Carolina Riveros: no relevant interests;
works as an epidemiologist. David Tovey: no relevant interests; Emeritus Editor in
Chief, Feedback Editors for 2 Cochrane review groups. Joerg J Meerpohl: no relevant
interests; member of the German Standing Vaccination Committee (STIKO). Giacomo
Grasselli: Pfizer – speaking engagement. Gabriel Rada: none known.
Asbjørn Hróbjartsson: no relevant interests; Cochrane Methodology Review
Group Editor. Philippe Ravaud: no relevant interests; involved with Mariette
CORIMUNO‐19 Collaborative 2021, the Ministry of Health, Programme Hospitalier
de Recherche Clinique, Foundation for Medical Research, and AP‐HP Foundation.
Anna Chaimani: none known. Isabelle Boutron: no relevant interests; member of
Cochrane Editorial Board.</CoiStatement>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2022</Year>
<Month>12</Month>
<Day>6</Day>
<Hour>19</Hour>
<Minute>26</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2022</Year>
<Month>12</Month>
<Day>7</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2022</Year>
<Month>12</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pmc-release">
<Year>2022</Year>
<Month>12</Month>
<Day>7</Day>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">36473651</ArticleId>
<ArticleId IdType="pmc">PMC9726273</ArticleId>
<ArticleId IdType="doi">10.1002/14651858.CD015477</ArticleId>
</ArticleIdList>
<ReferenceList>
<Title>References to studies included in this review</Title>
<ReferenceList>
<Title>Ali 2021 {published data only}</Title>
<Reference>
<Citation>Ali K, Berman G, Zhou H, Deng W, Faughnan V, Coronado-Voges M, et
al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. New
England Journal of Medicine 2021;385(24):2241-51.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8385554</ArticleId>
<ArticleId IdType="pubmed">34379915</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Al Kaabi 2021 {published data only}</Title>
<Reference>
<Citation>Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N,
et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic
COVID-19 infection in adults: a randomized clinical trial. JAMA
2021;326(1):35-45.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8156175</ArticleId>
<ArticleId IdType="pubmed">34037666</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Asano 2022 {published data only}</Title>
<Reference>
<Citation>Asano M, Okada H, Itoh Y, Hirata H, Ishikawa K, Yoshida E, et al.
Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against
SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2
trial. International Journal of Infectious Diseases 2022;114:165-74.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8531242</ArticleId>
<ArticleId IdType="pubmed">34688944</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Bonelli 2021 {published data only}</Title>
<Reference>
<Citation>Bonelli M, Mrak D, Tobudic S, Sieghart D, Koblischke M, Mandl P,
et al. Additional heterologous versus homologous booster vaccination in
immunosuppressed patients without SARS-CoV-2 antibody seroconversion
after primary mRNA vaccination: a randomized controlled trial. medRxiv
2021 [Preprint]. [DOI: 10.1101/2021.09.05.21263125]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1101/2021.09.05.21263125</ArticleId>
<ArticleId IdType="pubmed">35027397</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Bueno 2021 {published data only}</Title>
<Reference>
<Citation>Bueno SM, Abarca K, González PA, Gálvez NM, Soto JA,
Duarte LF, et al. Interim report: safety and immunogenicity of an
inactivated vaccine against SARS-CoV-2 in healthy Chilean adults in a
phase 3 clinical trial. medRxiv 2021 [Preprint]. [DOI:
10.1101/2021.03.31.21254494]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1101/2021.03.31.21254494</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Bueno SM, Abarca K, González PA, Gálvez NM, Soto JA,
Duarte LF, et al. Safety and immunogenicity of an inactivated SARS-CoV-2
vaccine in a subgroup of healthy adults in Chile. Clinical Infectious
Diseases 2021 Sep 19 [Epub ahead of print]. [DOI: 10.1093/cid/ciab823]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1093/cid/ciab823</ArticleId>
<ArticleId IdType="pmc">PMC9402626</ArticleId>
<ArticleId IdType="pubmed">34537835</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Clemens 2021 {published data only}</Title>
<Reference>
<Citation>Clemens SA, Folegatti PM, Emary KR, Weckx LY, Ratcliff J, Bibi S,
et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2
lineages circulating in Brazil. Nature Communications 2021;12(1):5861.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8494913</ArticleId>
<ArticleId IdType="pubmed">34615860</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Dunkle 2021 {published data only}</Title>
<Reference>
<Citation>Dunkle LM, Kotloff KL, Gay CL, Áñez G, Adelglass JM,
Barrat Hernández AQ, et al. Efficacy and safety of NVX-CoV2373 in
adults in the United States and Mexico. medRxiv 2021 [Preprint]. [DOI:
10.1101/2021.10.05.21264567]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1101/2021.10.05.21264567</ArticleId>
<ArticleId IdType="pmc">PMC8693692</ArticleId>
<ArticleId IdType="pubmed">34910859</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Ella 2021a {published data only}</Title>
<Reference>
<Citation>Ella R, Vadrevu KM, Jogdand H, Prasad S, Reddy S, Sarangi V, et
al. A Phase 1: safety and immunogenicity trial of an inactivated
SARS-CoV-2 vaccine-BBV152. medRxiv 2020 [Preprint]. [DOI:
10.1101/2020.12.11.20210419]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1101/2020.12.11.20210419</ArticleId>
<ArticleId IdType="pmc">PMC7825810</ArticleId>
<ArticleId IdType="pubmed">33485468</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ella R, Vadrevu KM, Jogdand H, Prasad S, Reddy S, Sarangi V, et
al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine,
BBV152: a double-blind, randomized, phase 1 trial. Lancet Infectious
Diseases 2021;21(5):637-46.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC7825810</ArticleId>
<ArticleId IdType="pubmed">33485468</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Ella 2021b {published data only}</Title>
<Reference>
<Citation>Ella R, Reddy S, Blackwelder W, Potdar V, Yadav P, Sarangi V, et
al. Efficacy, safety, and lot to lot immunogenicity of an inactivated
SARS-CoV-2 vaccine (BBV152): a double-blind, randomized, controlled
phase 3 trial. medRxiv 2021 [Preprint]. [DOI:
10.1101/2021.06.30.21259439]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1101/2021.06.30.21259439</ArticleId>
<ArticleId IdType="pmc">PMC8584828</ArticleId>
<ArticleId IdType="pubmed">34774196</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>El Sahly 2021 {published data only}</Title>
<Reference>
<Citation>Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et
al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England
Journal of Medicine 2021;384(5):403-16.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC7787219</ArticleId>
<ArticleId IdType="pubmed">33378609</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM,
Anderson EJ, et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at
completion of blinded phase. New England Journal of Medicine
2021;385(19):1774-85.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8482810</ArticleId>
<ArticleId IdType="pubmed">34551225</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Food and Drug Administration. Vaccines and Related Biological
Products Advisory Committee Meeting; December 17, 2020; FDA Briefing
Document: Moderna COVID-19 vaccine. www.fda.gov/media/144434/download
(accessed prior to 1 November 2022).</Citation>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Emary 2021 {published data only}</Title>
<Reference>
<Citation>Emary KR, Golubchik T, Aley PK, Ariani CV, Angus B, Bibi S, et al.
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant
of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomized
controlled trial. Lancet 2021;397(10282):1351-62.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8009612</ArticleId>
<ArticleId IdType="pubmed">33798499</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Fadlyana 2021 {published data only}</Title>
<Reference>
<Citation>Fadlyana E, Rusmil K, Tarigan R, Rahmadi AR, Prodjosoewojo S,
Sofiatin Y, et al. A phase III, observer-blind, randomized,
placebo-controlled study of the efficacy, safety, and immunogenicity of
SARS-CoV-2 inactivated vaccine in healthy adults aged
18–59 years: an interim analysis in Indonesia. Vaccine
2021;39(44):6520-8.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8461222</ArticleId>
<ArticleId IdType="pubmed">34620531</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Falsey 2021 {published data only}</Title>
<Reference>
<Citation>Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Robb ML, Corey L,
et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19
vaccine. New England Journal of Medicine 2021;385(25):2348-60.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8522798</ArticleId>
<ArticleId IdType="pubmed">34587382</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Formica 2021 {published data only}</Title>
<Reference>
<Citation>Formica N, Mallory R, Albert G, Robinson M, Plested JS, Cho I, et
al. Different dose regimens of a SARS-CoV-2 recombinant spike protein
vaccine (NVX-CoV2373) in younger and older adults: a phase 2 randomized
placebo-controlled trial. PLOS Medicine 2021;18(10):e1003769.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8486115</ArticleId>
<ArticleId IdType="pubmed">34597298</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Formica N, Mallory R, Albert G, Robinson M, Plested JS, Cho I, et
al. Evaluation of a SARS-CoV-2 vaccine NVX-CoV2373 in younger and older
adults. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.26.21252482]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1101/2021.02.26.21252482</ArticleId>
<ArticleId IdType="pmc">PMC8486115</ArticleId>
<ArticleId IdType="pubmed">34597298</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Frenck 2021 {published data only}</Title>
<Reference>
<Citation>Frenck RW Jr, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart
S, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19
vaccine in adolescents. New England Journal of Medicine
2021;385(3):239-50.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8174030</ArticleId>
<ArticleId IdType="pubmed">34043894</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Guo 2021 {published data only}</Title>
<Reference>
<Citation>Guo W, Duan K, Zhang Y, Yuan Z, Zhang YB, Wang Z, et al. Safety
and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy
adults aged 18 years or older: a randomized, double-blind,
placebo-controlled, phase 1/2 trial. eClinicalMedicine 2021;38:101010.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8260504</ArticleId>
<ArticleId IdType="pubmed">34250456</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Hall 2021 {published data only}</Title>
<Reference>
<Citation>Hall VG, Ferreira VH, Ku T, Ierullo M, Majchrzak-Kita B, Chaparro
C, et al. Randomized trial of a third dose of mRNA-1273 vaccine in
transplant recipients. New England Journal of Medicine
2021;385(13):1244-6.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8385563</ArticleId>
<ArticleId IdType="pubmed">34379917</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Han 2021 {published data only}</Title>
<Reference>
<Citation>Han B, Song Y, Li C, Yang W, Ma Q, Jiang Z, et al. Safety,
tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine
(CoronaVac) in healthy children and adolescents: a double-blind,
randomized, controlled, phase 1/2 clinical trial. Lancet Infectious
Diseases 2021;21(12):1645-53.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8238449</ArticleId>
<ArticleId IdType="pubmed">34197764</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Heath 2021 {published data only}</Title>
<Reference>
<Citation>Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et
al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. New England
Journal of Medicine 2021;385(13):1172-83.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8262625</ArticleId>
<ArticleId IdType="pubmed">34192426</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et
al . Efficacy of the NVX-CoV2373 Covid-19 vaccine against the B.
1.1.7 variant. medRxiv 2021 [Preprint].</Citation>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Keech 2020 {published data only}</Title>
<Reference>
<Citation>Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, et al.
Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle
vaccine. New England Journal of Medicine  2020;383:2320-32.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC7494251</ArticleId>
<ArticleId IdType="pubmed">32877576</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Kremsner 2021 {published data only}</Title>
<Reference>
<Citation>Kremsner PG, Ahuad Guerrero RA, Arana-Arri E, Aroca Martinez GJ,
Bonten M, Chandler R, et al. Efficacy and safety of the CVnCoV
SARS-CoV-2 mRNA vaccine candidate: results from Herald, a phase 2b/3,
randomized, observer-blinded, placebo-controlled clinical trial in ten
countries in Europe and Latin America. SSRN 2021 [Preprint]. [DOI:
10.2139/ssrn.3911826]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.2139/ssrn.3911826</ArticleId>
<ArticleId IdType="pmc">PMC8610426</ArticleId>
<ArticleId IdType="pubmed">34826381</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Kulkarni 2021 {published data only}</Title>
<Reference>
<Citation>Kulkarni PS, Padmapriyadarsini C, Vekemans J, Bavdekar A, Gupta M,
Kulkarni P, et al. A phase 2/3, observer-blind, randomized, controlled
study to assess the safety and immunogenicity of SII-ChAdOx1 nCOV-19
(COVID-19 vaccine) in adults in India. eClinicalMedicine 2021;42:101218.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8629682</ArticleId>
<ArticleId IdType="pubmed">34870133</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Li 2021a {published data only}</Title>
<Reference>
<Citation>Li J, Hou L, Guo X, Jin P, Wu S, Zhu J, et al. Heterologous
prime-boost immunization with CoronaVac and Convidecia. medRxiv 2021
[Preprint]. [DOI: 10.1101/2021.09.03.21263062]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1101/2021.09.03.21263062</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Liu 2021 {published data only}</Title>
<Reference>
<Citation>Liu X, Shaw RH, Stuart AS, Greenland M, Aley PK, Andrews NJ, et
al. Safety and immunogenicity of heterologous versus homologous
prime-boost schedules with an adenoviral vectored and mRNA COVID-19
vaccine (Com-COV): a single-blind, randomized, non-inferiority trial.
Lancet 2021;398(10303):856-69.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8346248</ArticleId>
<ArticleId IdType="pubmed">34370971</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Liu X, Shaw RH, Stuart AS, Greenland M, Aley PK, Andrews NJ, et
al. Safety and immunogenicity report from the Com-COV Study – a
single-blind randomized non-inferiority trial comparing heterologous and
homologous prime-boost schedules with an adenoviral vectored and mRNA
COVID-19 vaccine. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3874014]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.2139/ssrn.3874014</ArticleId>
<ArticleId IdType="pmc">PMC8346248</ArticleId>
<ArticleId IdType="pubmed">34370971</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Logunov 2021 {published data only}</Title>
<Reference>
<Citation>Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI,
Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and
rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim
analysis of a randomized controlled phase 3 trial in Russia. Lancet
2021;397(10275):671-81.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC7852454</ArticleId>
<ArticleId IdType="pubmed">33545094</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Madhi 2021a {published data only}</Title>
<Reference>
<Citation>Madhi SA, Koen AL, Izu A, Fairlie L, Cutland CL, Baillie V, et al.
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine
against SARS-CoV-2 in people living with and without HIV in South
Africa: an interim analysis of a randomized, double-blind,
placebo-controlled, phase 1B/2A trial. Lancet HIV 2021;8(9):e568-80.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8372504</ArticleId>
<ArticleId IdType="pubmed">34416193</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Madhi 2021b {published data only}</Title>
<Reference>
<Citation>Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, et
al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351
variant. New England Journal of Medicine 2021;384(20):1885-98.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC7993410</ArticleId>
<ArticleId IdType="pubmed">33725432</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Mok 2021 {published data only}</Title>
<Reference>
<Citation>Mok C, Cheng S, Chen C, Yiu K, Chan TO, Lai KC, et al. A RCT of a
third dose CoronaVac or BNT162b2 vaccine in adults with two doses of
CoronaVac. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.11.02.21265843]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1101/2021.11.02.21265843</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Palacios 2020 {published data only}</Title>
<Reference>
<Citation>Palacios R, Patiño EG, Oliveira Piorelli R, Conde MT, Batista
AP, Zeng G, et al. Double-blind, randomized, placebo-controlled phase
III clinical trial to evaluate the efficacy and safety of treating
healthcare professionals with the adsorbed COVID-19 (inactivated)
vaccine manufactured by Sinovac – PROFISCOV: a structured summary
of a study protocol for a randomized controlled trial. Trials
2020;21(1):853.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC7558252</ArticleId>
<ArticleId IdType="pubmed">33059771</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Sablerolles 2021 {published data only}</Title>
<Reference>
<Citation>Sablerolles RS, Rietdijk WJ, Goorhuis A, Postma DF, Visser LG,
Geers D, et al. Immunogenicity and reactogenicity of booster
vaccinations after Ad26.COV2.S priming. medRxiv 2021 [Preprint]. [DOI:
10.1101/2021.10.18.21264979]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1101/2021.10.18.21264979</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Sadoff 2021a {published data only}</Title>
<Reference>
<Citation>Food and Drug Administration. Vaccines and related biological
products Advisory Committee Meeting; February 26, 2021; FDA briefing
document: Janssen Ad26.COV2.S vaccine for the prevention of COVID-19.
www.fda.gov/media/146217/download (accessed prior to 1 November 2022).</Citation>
</Reference>
<Reference>
<Citation>Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, Groot AM,
et al. Interim results of a Phase 1-2a trial of Ad26.COV2.S Covid-19
vaccine. New England Journal of Medicine 2021;384(19):1824-35.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC7821985</ArticleId>
<ArticleId IdType="pubmed">33440088</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, Groot AM,
et al. Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine
candidate: interim results of a phase 1/2a, double-blind, randomized,
placebo-controlled trial. medRxiv 2020 [Preprint]. [DOI:
10.1101/2020.09.23.20199604]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1101/2020.09.23.20199604</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Sadoff 2021b {published data only}</Title>
<Reference>
<Citation>Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G,
Grinsztejn B, et al. Safety and efficacy of single-dose Ad26.COV2.S
vaccine against Covid-19. New England Journal of Medicine
2021;384(23):2187-201.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8220996</ArticleId>
<ArticleId IdType="pubmed">33882225</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Shinde 2021 {published data only}</Title>
<Reference>
<Citation>Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L, et
al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351
variant. New England Journal of Medicine 2021;384(20):1899-909.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8091623</ArticleId>
<ArticleId IdType="pubmed">33951374</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L, et
al. Preliminary efficacy of the NVX-CoV2373 Covid-19 vaccine against the
B.1.351 variant. medRxiv 2021 [Preprint]. [DOI:
10.1101/2021.02.25.21252477]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1101/2021.02.25.21252477</ArticleId>
<ArticleId IdType="pmc">PMC8091623</ArticleId>
<ArticleId IdType="pubmed">33951374</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Tanriover 2021 {published data only}</Title>
<Reference>
<Citation>Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A,
Akhan S, et al. Efficacy and safety of an inactivated whole-virion
SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind,
randomized, placebo-controlled, phase 3 trial in Turkey. Lancet
2021;398(10296):213-22.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8266301</ArticleId>
<ArticleId IdType="pubmed">34246358</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Thomas 2021 {published data only}</Title>
<Reference>
<Citation>Food and Drug Administration. Vaccines and related biological
products Advisory Committee Meeting; December 10, 2020; FDA briefing
document: Pfizer-BioNTech COVID-19 vaccine.
www.fda.gov/media/144245/download (accessed prior to 1 November 2022).</Citation>
</Reference>
<Reference>
<Citation>Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S,
et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New
England Journal of Medicine 2020;383(27):2603-15.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC7745181</ArticleId>
<ArticleId IdType="pubmed">33301246</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Thomas SJ, Moreira ED Jr, Kitchin N, Absalon J, Gurtman A,
Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19
vaccine through 6 months. New England Journal of Medicine
2021;385(19):1761-773.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8461570</ArticleId>
<ArticleId IdType="pubmed">34525277</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Thomas SJ, Moreira ED Jr, Kitchin N, Absalon J, Gurtman A,
Lockhart S, et al. Six month safety and efficacy of the BNT162b2 mRNA
COVID-19 vaccine. medRxiv 2021 [Preprint]. [DOI:
10.1101/2021.07.28.21261159]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1101/2021.07.28.21261159</ArticleId>
<ArticleId IdType="pmc">PMC8461570</ArticleId>
<ArticleId IdType="pubmed">34525277</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Toledo‐Romani 2021 {published data only}</Title>
<Reference>
<Citation>Toledo-Romani ME, Garcia-Carmenate M, Silva-Valenzuela C,
Baldoquin-Rodriguez W, Martínez-Pérez M,
Rodríguez-González M, et al. Safety and efficacy of the two
doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a
heterologous three-dose combination with SOBERANA-PLUS: double-blind,
randomized, placebo-controlled phase 3 clinical trial. medRxiv 2021
[Preprint]. [DOI: 10.1101/2021.10.31.21265703]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1101/2021.10.31.21265703</ArticleId>
<ArticleId IdType="pmc">PMC9803910</ArticleId>
<ArticleId IdType="pubmed">36618081</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Voysey 2021a {published data only}</Title>
<Reference>
<Citation>Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S,
Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1
nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2,
single-blind, randomized controlled trial. Lancet
2020;396(10249):467-78. [PMID: ]</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC7445431</ArticleId>
<ArticleId IdType="pubmed">32702298</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Voysey M, Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK,
et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222)
against SARS-CoV-2: an interim analysis of four randomized controlled
trials in Brazil, South Africa, and the UK. Lancet
2021;397(10269):99-111. [PMID: ]</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC7723445</ArticleId>
<ArticleId IdType="pubmed">33306989</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Walsh 2020 {published data only}</Title>
<Reference>
<Citation>Walsh EE, Frenck R, Falsey AR, Kitchin N, Absalon J, Gurtman A, et
al. RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy
study. medRxiv 2020 [Preprint]. [DOI: 10.1101/2020.08.17.20176651]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1101/2020.08.17.20176651</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman
A, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine
candidates. New England Journal of Medicine 2020;383(25):2439-50.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC7583697</ArticleId>
<ArticleId IdType="pubmed">33053279</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Wu 2021a {published data only}</Title>
<Reference>
<Citation>Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z, et al. Safety,
tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine
(CoronaVac) in healthy adults aged 60 years and older: a randomized,
double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet
Infectious Diseases 2021;21(6):803-12.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC7906628</ArticleId>
<ArticleId IdType="pubmed">33548194</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Xia 2020 {published data only}</Title>
<Reference>
<Citation>Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, et al. Effect of
an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity
outcomes: interim analysis of 2 randomized clinical trials. JAMA
2020;324(10):951-60.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC7426884</ArticleId>
<ArticleId IdType="pubmed">32789505</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and
immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a
randomized, double-blind, placebo-controlled, phase 1/2 trial. Lancet
Infectious Diseases 2020;21(1):39-51.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC7561304</ArticleId>
<ArticleId IdType="pubmed">33069281</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Xia 2021 {published data only}</Title>
<Reference>
<Citation>Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and
immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people
younger than 18 years: a randomized, double-blind, controlled, phase 1/2
trial. Lancet Infectious Diseases 2021;22(2):196-208.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8443232</ArticleId>
<ArticleId IdType="pubmed">34536349</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Zhang 2021 {published data only}</Title>
<Reference>
<Citation>Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety,
tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in
healthy adults aged 18–59 years: a randomized, double-blind,
placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases
2021;21(2):181-92.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC7832443</ArticleId>
<ArticleId IdType="pubmed">33217362</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</ReferenceList>
<ReferenceList>
<Title>References to studies excluded from this review</Title>
<ReferenceList>
<Title>Baden 2021 {published data only}</Title>
<Reference>
<Citation>Baden LR, El Sahly HM, Essink B, Follmann D, Neuzil KM, August A,
et al. Covid-19 in the phase 3 trial of mRNA-1273 during the
Delta-variant surge. medRxiv 2021 [Preprint]. [DOI:
10.1101/2021.09.17.21263624]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1101/2021.09.17.21263624</ArticleId>
<ArticleId IdType="pmc">PMC8609569</ArticleId>
<ArticleId IdType="pubmed">34731553</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Barrett 2021 {published data only}</Title>
<Reference>
<Citation>Barrett JR, Belij-Rammerstorfer S, Dold C, Ewer KJ, Folegatti PM,
Gilbride C, et al. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19
with a booster dose induces multifunctional antibody responses. Nature
Medicine 2021;27(2):279-88.</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">33335322</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Ewer 2021 {published data only}</Title>
<Reference>
<Citation>Ewer KJ, Barrett JR, Belij-Rammerstorfer S, Sharpe H, Makinson R,
Morter R, et al. T cell and antibody responses induced by a single dose
of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Nature Medicine 2021;27(2):270-8.</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">33335323</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Flaxman 2021 {published data only}</Title>
<Reference>
<Citation>Flaxman A, Marchevsky NG, Jenkin D, Aboagye J, Aley PK, Angus B,
et al. Reactogenicity and immunogenicity after a late second dose or a
third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomized
controlled trials (COV001 and COV002). Lancet 2021;398(10304):981-90.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8409975</ArticleId>
<ArticleId IdType="pubmed">34480858</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Hsieh 2021 {published data only}</Title>
<Reference>
<Citation>Hsieh SM, Liu WD, Huang YS, Lin YJ, Hsieh EF, Lian WC, et al.
Safety and immunogenicity of a recombinant stabilized prefusion
SARS-CoV-2 spike protein vaccine (MVC-COV1901) adjuvanted with CpG 1018
and aluminum hydroxide in healthy adults: a phase 1, dose-escalation
study. eClinicalMedicine 2021;38:100989.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8233066</ArticleId>
<ArticleId IdType="pubmed">34222848</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Irfan 2021 {published data only}</Title>
<Reference>
<Citation>Irfan N, Chagla Z. In South Africa, a 2-dose Oxford/AZ vaccine did
not prevent mild to moderate COVID-19 (cases mainly B.1.351 variant).
Annals of Internal Medicine 2021;174(5):JC50.</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">33939483</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Lazarus 2021 {published data only}</Title>
<Reference>
<Citation>Lazarus R, Baos S, Cappel-Porter H, Carson-Stevens A, Clout M,
Culliford L, et al. The safety and immunogenicity of concomitant
administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal
influenza vaccines in adults: a phase IV, multicentre randomized
controlled trial with blinding (ComFluCOV). SSRN 2021 [Preprint]. [DOI:
10.2139/ssrn.3931758]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.2139/ssrn.3931758</ArticleId>
<ArticleId IdType="pmc">PMC8585490</ArticleId>
<ArticleId IdType="pubmed">34774197</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Patamatamkul 2021 {published data only}</Title>
<Reference>
<Citation>Patamatamkul S, Thammawat S, Buranrat B. Induction of robust
neutralizing antibodies against the COVID-19 Delta variant with ChAdOx1
nCoV-19 or BNT162b2 as a booster following a primary vaccination series
with CoronaVac. medRxiv 2021 [Preprint]. [DOI:
10.1101/2021.09.25.21264099]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1101/2021.09.25.21264099</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Ward 2021a {published data only}</Title>
<Reference>
<Citation>Ward BJ, Séguin A, Couillard J, Trépanier S, Landry N.
Phase III: randomized observer-blind trial to evaluate lot-to-lot
consistency of a new plant-derived quadrivalent virus like particle
influenza vaccine in adults 18-49 years of age. Vaccine
2021;39(10):1528-33.</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">33581920</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Wu 2021b {published data only}</Title>
<Reference>
<Citation>Wu K, Choi A, Koch M, Ma LZ, Hill A, Nunna N, et al. Preliminary
analysis of safety and immunogenicity of a SARS-CoV-2 variant vaccine
booster. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.05.05.21256716]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1101/2021.05.05.21256716</ArticleId>
<ArticleId IdType="pmc">PMC8604720</ArticleId>
<ArticleId IdType="pubmed">34526698</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Zdanowski 2021 {published data only}</Title>
<Reference>
<Citation>Zdanowski W, Waśniewski T. Evaluation of SARS-CoV-2 spike
protein antibody titers in cord blood after COVID-19 vaccination during
pregnancy in Polish healthcare workers: preliminary results. Vaccines
2021;9(6):675.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8234119</ArticleId>
<ArticleId IdType="pubmed">34205434</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</ReferenceList>
<ReferenceList>
<Title>Additional references</Title>
<ReferenceList>
<Title>Abbasi 2020</Title>
<Reference>
<Citation>Abbasi J. COVID-19 and mRNA vaccines – first large test for
a new approach. JAMA 2020;324(12):1125-7.</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32880613</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Angkasekwinai 2022</Title>
<Reference>
<Citation>Angkasekwinai N, Sewatanon J, Niyomnaitham S, Phumiamorn S,
Sukapirom K, Sapsutthipas S, et al. Comparison of safety and
immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2
circulating variants of concern (Alpha, Delta, Beta) in Thai healthcare
workers. Vaccine X 2022;10:100153.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8896862</ArticleId>
<ArticleId IdType="pubmed">35282410</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Attaway 2021</Title>
<Reference>
<Citation>Attaway AH, Scheraga RG, Bhimraj A, Biehl M, Hatipoğlu U.
Severe Covid-19 pneumonia: pathogenesis and clinical management. BMJ
2021;372:n436.</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">33692022</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Baden 2021</Title>
<Reference>
<Citation>Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et
al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England
Journal of Medicine 2021;384(5):403-16.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC7787219</ArticleId>
<ArticleId IdType="pubmed">33378609</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Balduzzi 2019</Title>
<Reference>
<Citation>Balduzzi S, Rücker G, Schwarzer G. How to perform a
meta-analysis with R: a practical tutorial. Evidence-Based Mental Health
2019;22:153-60.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC10231495</ArticleId>
<ArticleId IdType="pubmed">31563865</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Borobia 2021</Title>
<Reference>
<Citation>Borobia AM, Carcas AJ, Pérez-Olmeda M, Castaño L,
Bertran MJ, García-Pérez J, et al. Immunogenicity and
reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants
(CombiVacS): a multicentre, open-label, randomised, controlled, phase 2
trial. Lancet 2021;398(10295):121-30.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8233007</ArticleId>
<ArticleId IdType="pubmed">34181880</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Boutron 2020a</Title>
<Reference>
<Citation>Boutron I, Chaimani A, Meerpohl JJ, Hróbjartsson A, Devane D,
Rada G, et al. The COVID-NMA Project: building an evidence ecosystem for
the COVID-19 pandemic. Annals of Internal Medicine 2020;173(12):1015-7.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC7518109</ArticleId>
<ArticleId IdType="pubmed">32931326</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Boutron 2020b</Title>
<Reference>
<Citation>Boutron I, Chaimani A, Meerpohl JJ, Hróbjartsson A, Devane D,
Rada G, et al. Interventions for preventing and treating COVID-19:
protocol for a living mapping of research and a living systematic
review. Cochrane Database of Systematic Reviews 2020, Issue 11. Art. No:
CD013769. [DOI: 10.1002/14651858.CD013769]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1002/14651858.CD013769</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Bucci 2021</Title>
<Reference>
<Citation>Bucci EM, Berkhof J, Gillibert A, Gopalakrishna G, Calogero RA,
Bouter LM, et al. Data discrepancies and substandard reporting of
interim data of Sputnik V phase 3 trial. Lancet 2021;397(10288):1881-3.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC9751705</ArticleId>
<ArticleId IdType="pubmed">33991475</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Bueno 2021</Title>
<Reference>
<Citation>Bueno SM, Abarca K, González PA, Gálvez NM, Soto JA,
Duarte LF, et al. Interim report: safety and immunogenicity of an
inactivated vaccine against SARS-CoV-2 in healthy Chilean adults in a
phase 3 clinical trial. medRxiv 2021 [Preprint].</Citation>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Cabanac 2021</Title>
<Reference>
<Citation>Cabanac G, Oikonomidi T, Boutron I. Day-to-day discovery of
preprint-publication links. Scientometrics 2021;126(6):5285-304.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8053368</ArticleId>
<ArticleId IdType="pubmed">33897069</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Castagneto Gissey 2021</Title>
<Reference>
<Citation>Castagneto Gissey L, Panunzi S, Maltese S, Russo MF, Angelini G,
De Gaetano A, et al. Living systematic meta-analysis of COVID-19
vaccines and dose allocation strategies. SSRN  2021 [Preprint].
[DOI: 10.2139/ssrn.3827806]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.2139/ssrn.3827806</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>CDC 2021</Title>
<Reference>
<Citation>Centers for Disease Control and Prevention. Understanding mRNA
COVID-19 vaccines.
www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/mrna.html
(accessed prior to 1 November 2022).</Citation>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Chaimani 2013</Title>
<Reference>
<Citation>Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G.
Graphical tools for network meta-analysis in STATA. PLOS One 
2013;8 (10):e76654.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC3789683</ArticleId>
<ArticleId IdType="pubmed">24098547</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Chaimani 2015</Title>
<Reference>
<Citation>Chaimani A, Salanti G. Visualizing assumptions and results in
network meta-analysis: the Network Graphs Package. Stata Journal
2015;15(4):905-50.</Citation>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Chaimani 2022</Title>
<Reference>
<Citation>Chaimani A, Caldwell DM, Li T, Higgins JP, Salanti G. Chapter 11:
Undertaking network meta-analyses. In: Higgins JP, Thomas J, Chandler J,
Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for
Systematic Reviews of Interventions Version 6.3 (updated February 2022).
Cochrane, 2022. Available from training.cochrane.org/handbook.</Citation>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Chappell 2021</Title>
<Reference>
<Citation>Chappell KJ, Mordant FL, Li Z, Wijesundara DK, Ellenberg P,
Lackenby JA, et al. Safety and immunogenicity of an MF59-adjuvanted
spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised,
double-blind, placebo-controlled, phase 1 trial. Lancet Infectious
Diseases 2021;21(10):1383-94.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8055208</ArticleId>
<ArticleId IdType="pubmed">33887208</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Che 2021</Title>
<Reference>
<Citation>Che Y, Liu X, Pu Y, Zhou M, Zhao Z, Jiang R, et al. Randomized,
double-blinded, placebo-controlled Phase 2 trial of an inactivated
severe acute respiratory syndrome coronavirus 2 vaccine in healthy
adults. Clinical Infectious Diseases 2021;73(11):e3949-55.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC7717222</ArticleId>
<ArticleId IdType="pubmed">33165503</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Chu 2021</Title>
<Reference>
<Citation>Chu L, McPhee R, Huang W, Bennett H, Pajon R, Nestorova B, et al.
A preliminary report of a randomized controlled phase 2 trial of the
safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine
2021;39(20):2791-9.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC7871769</ArticleId>
<ArticleId IdType="pubmed">33707061</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Dal‐Ré 2021a</Title>
<Reference>
<Citation>Dal-Ré R, Bekker LG, Gluud C, Holm S, Jha V, Poland GA, et
al. Ongoing and future COVID-19 vaccine clinical trials: challenges and
opportunities. Lancet Infectious Diseases 2021;21(11):e342-7.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8131060</ArticleId>
<ArticleId IdType="pubmed">34019801</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Dal‐Ré 2021b</Title>
<Reference>
<Citation>Dal-Ré R, Orenstein W, Caplan AL. Being fair to participants
in placebo-controlled COVID-19 vaccine trials. Nature Medicine
2021;27(6):938.</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">33903751</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>DeZure 2016</Title>
<Reference>
<Citation>DeZure AD, Berkowitz NM, Graham BS, Ledgerwood JE.
Whole-inactivated and virus-like particle vaccine strategies for
chikungunya virus. Journal of Infectious Diseases 2016;214(Suppl
5):S497-9.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC5137244</ArticleId>
<ArticleId IdType="pubmed">27920180</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Dias 2010</Title>
<Reference>
<Citation>Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in
mixed treatment comparison meta-analysis. Statistics in Medicine
2010;29(7-8):932-44.</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20213715</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Dong 2020</Title>
<Reference>
<Citation>Dong Y, Dai T, Wei Y, Zhang L, Zheng M, Zhou F. A systematic
review of SARS-CoV-2 vaccine candidates. Signal Transduction and
Targeted Therapy 2020;5(1):237.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC7551521</ArticleId>
<ArticleId IdType="pubmed">33051445</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Egger 1997</Title>
<Reference>
<Citation>Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis
detected by a simple, graphical test. BMJ 1997;315:629-34.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC2127453</ArticleId>
<ArticleId IdType="pubmed">9310563</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Ella 2020b</Title>
<Reference>
<Citation>Ella R, Reddy S, Jogdand H, Sarangi V, Ganneru B, Prasad S, et al.
Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2
vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial)
and the persistence of immune responses from a phase 1 follow-up report.
medRxiv  2020 [Preprint]. [DOI: 10.1101/2020.12.21.20248643]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1101/2020.12.21.20248643</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Ella 2021a</Title>
<Reference>
<Citation>Ella R, Reddy S, Jogdand H, Sarangi V, Ganneru B, Prasad S, et al.
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152:
interim results from a double-blind, randomized, multicentre, phase 2
trial, and 3-month follow-up of a double-blind, randomized phase 1
trial. Lancet Infectious Diseases 2021;21(7):950-61.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8221739</ArticleId>
<ArticleId IdType="pubmed">33705727</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Enjuanes 2016</Title>
<Reference>
<Citation>Enjuanes L, Zuñiga S, Castaño-Rodriguez C,
Gutierrez-Alvarez J, Canton J, Sola I. Molecular basis of coronavirus
virulence and vaccine development. Advances in Virus Research
2016;96:245-86.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC7112271</ArticleId>
<ArticleId IdType="pubmed">27712626</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Epistemonikos</Title>
<Reference>
<Citation>Epistemonikos. Epistemonikos L·OVE COVID-19 platform.
Available at
app.iloveevidence.com/loves/5e6fdb9669c00e4ac072701d?utm=ile.</Citation>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>FDA 2020a</Title>
<Reference>
<Citation>Food and Drug Administration. Development and licensure of
vaccines to prevent COVID-19. Guidance for industry; June 2020.
www.fda.gov/media/139638/download (accessed prior to 1 November 2022).</Citation>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>FDA 2020b</Title>
<Reference>
<Citation>Food and Drug Administration. FDA Briefing Document Moderna
COVID-19 Vaccine. Vaccines and Related Biological Products Advisory
Committee Meeting December 17, 2020. www.fda.gov/media/144434/download
(accessed prior to 1 November 2022).</Citation>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>FDA 2020c</Title>
<Reference>
<Citation>Food and Drug Administration. FDA Briefing Document
Pfizer-BioNTech COVID-19 Vaccine. Vaccines and Related Biological
Products Advisory Committee Meeting December 10, 2020.
www.fda.gov/media/144245/download (accessed prior to 1 November 2022).</Citation>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>FDA 2021</Title>
<Reference>
<Citation>Food and Drug Administration. FDA Briefing Document Janssen
Ad26.COV2.S Vaccine for the Prevention of COVID-19. Vaccines and Related
Biological Products Advisory Committee Meeting February 26, 2021.
www.fda.gov/media/146217/download (accessed prior to 1 November 2022).</Citation>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Feikin 2022</Title>
<Reference>
<Citation>Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg
Y, et al. Duration of effectiveness of vaccines against SARS-CoV-2
infection and COVID-19 disease: results of a systematic review and
meta-regression. Lancet 2022;399(10328):924-44.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8863502</ArticleId>
<ArticleId IdType="pubmed">35202601</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Feng 2021</Title>
<Reference>
<Citation>Feng Y, Chen J, Yao T, Chang Y, Li X, Xing R, et al. Safety and
Immunogenicity of Inactivated SARS-CoV-2 vaccine in high-risk
occupational population: a randomized, parallel, controlled clinical
trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.08.06.21261696]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1101/2021.08.06.21261696</ArticleId>
<ArticleId IdType="pmc">PMC8692079</ArticleId>
<ArticleId IdType="pubmed">34933684</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Folegatti 2020</Title>
<Reference>
<Citation>Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S,
Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1
nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2,
single-blind, randomised controlled trial. Lancet 2020;396:467-78.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC7445431</ArticleId>
<ArticleId IdType="pubmed">32702298</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Formica 2021</Title>
<Reference>
<Citation>Formica N, Mallory R, Albert G, Robinson M, Plested JS, Cho I, et
al, the 2019nCoV-101 Study Group. Evaluation of a SARS-CoV-2 vaccine
NVX-CoV2373 in younger and older adults. medRxiv 2021 [Preprint]. [DOI:
10.1101/2021.02.26.21252482]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1101/2021.02.26.21252482</ArticleId>
<ArticleId IdType="pmc">PMC8486115</ArticleId>
<ArticleId IdType="pubmed">34597298</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Fuenmayor 2017</Title>
<Reference>
<Citation>Fuenmayor J, Gòdia F, Cervera L. Production of virus-like
particles for vaccines. New Biotechnology 2017;39(Pt B):174-80.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC7102714</ArticleId>
<ArticleId IdType="pubmed">28778817</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Gavi 2020</Title>
<Reference>
<Citation>Gavi. What are viral vector-based vaccines and how could they be
used against COVID-19?
www.gavi.org/vaccineswork/what-are-viral-vector-based-vaccines-and-how-could-they-be-used-against-covid-19
(accessed prior to 1 November 2022).</Citation>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Gobeil 2021</Title>
<Reference>
<Citation>Gobeil P, Pillet S, Séguin A, Boulay I, Mahmood A, Vinh DC,
et al. Interim report of a Phase 2 randomized trial of a plant-produced
virus-like particle vaccine for Covid-19 in healthy adults aged 18-64
and older adults aged 65 and older. medRxiv  2021 [Preprint]. [DOI:
10.1101/2021.05.14.21257248]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1101/2021.05.14.21257248</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Goepfert 2021</Title>
<Reference>
<Citation>Goepfert PA, Fu B, Chabanon AL, Bonaparte MI, Davis MG, Essink BJ,
et al. Safety and immunogenicity of SARS-CoV-2 recombinant protein
vaccine formulations in healthy adults: interim results of a randomised,
placebo-controlled, phase 1-2, dose-ranging study. Lancet Infectious
Diseases 2021;21(9):1257-70.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8055206</ArticleId>
<ArticleId IdType="pubmed">33887209</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>GRADEpro GDT [Computer program]</Title>
<Reference>
<Citation>GRADEpro GDT. Version accessed 6 December 2021. Hamilton (ON):
McMaster University (developed by Evidence Prime). Available at
gradepro.org.</Citation>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Guyatt 2011</Title>
<Reference>
<Citation>Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et
al. GRADE guidelines 6. Rating the quality of evidence –
imprecision. Journal of Clinical Epidemiology 2011;64(12):1283-93.</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21839614</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Harder 2021</Title>
<Reference>
<Citation>Harder T, Koch J, Vygen-Bonnet S, Kulper-Schiek W, Pilic A, Reda
S, et al. Efficacy and effectiveness of COVID-19 vaccines against
SARS-CoV-2 infection: interim results of a living systematic review, 1
January to 14 May 2021. Eurosurveillance 2021;26(28):2100563.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8284046</ArticleId>
<ArticleId IdType="pubmed">34269175</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Hayawi 2021</Title>
<Reference>
<Citation>Hayawi K, Shahriar S, Serhani MA, Alashwal H, Masud MM. Vaccine
versus variants (3Vs): are the COVID-19 vaccines effective against the
variants? A systematic review. Vaccines 2021;9(11):1305.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8622454</ArticleId>
<ArticleId IdType="pubmed">34835238</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Heath 2021 </Title>
<Reference>
<Citation>Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et
al. Efficacy of the NVX-CoV2373 Covid-19 vaccine against the B.1.1.7
variant. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.05.13.21256639]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1101/2021.05.13.21256639</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Higdon 2021</Title>
<Reference>
<Citation>Higdon MM, Wahl B, Jones CB, Rosen JG, Truelove SA, Baidya A, et
al. A systematic review of COVID-19 vaccine efficacy and effectiveness
against SARS-CoV-2 infection and disease. medRxiv 2021 [Preprint]. [DOI:
10.1101/2021.09.17.21263549]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1101/2021.09.17.21263549</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Higgins 2021</Title>
<Reference>
<Citation>Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch
VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions
Version 6.2 (updated February 2021). Cochrane, 2021. Available from
training.cochrane.org/handbook/archive/v6.2.</Citation>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Hobernik 2018</Title>
<Reference>
<Citation>Hobernik D, Bros M. DNA vaccines – how far from clinical
use? International Journal of Molecular Sciences 2018;19(11):3605.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC6274812</ArticleId>
<ArticleId IdType="pubmed">30445702</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Hultcrantz 2017</Title>
<Reference>
<Citation>Hultcrantz M, Rind D, Akl EA, Treweek S, Mustafa RA, Iorio A, et
al. The GRADE Working Group clarifies the construct of certainty of
evidence. Journal of Clinical Epidemiology 2017;87:4-13.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC6542664</ArticleId>
<ArticleId IdType="pubmed">28529184</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Kirkham 2018</Title>
<Reference>
<Citation>Kirkham JJ, Altman DG, Chan AW, Gamble C, Dwan KM, Williamson PR.
Outcome reporting bias in trials: a methodological approach for
assessment and adjustment in systematic reviews. BMJ 2018;362:k3802.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC6161807</ArticleId>
<ArticleId IdType="pubmed">30266736</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Korang 2022</Title>
<Reference>
<Citation>Korang SK, Rohden E, Veroniki AA, Ong G, Ngalamika O, Siddiqui F,
et al. Vaccines to prevent COVID-19: a living systematic review with
trial sequential analysis and network meta-analysis of randomized
clinical trials. PLOS One 2022;17(1):e0260733.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8782520</ArticleId>
<ArticleId IdType="pubmed">35061702</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Kow 2022</Title>
<Reference>
<Citation>Kow CS, Ramachandram DS, Hasan SS. The effectiveness of mRNA-1273
vaccine against COVID-19 caused by Delta variant: a systematic review
and meta-analysis. Journal of Medical Virology 2022;94(5):2269-74.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC9015635</ArticleId>
<ArticleId IdType="pubmed">34978339</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Lazarus 2021</Title>
<Reference>
<Citation>Lazarus R, Taucher C, Brown C, Čorbic I, Danon L, Dubischar
K, et al. Immunogenicity and safety of inactivated whole virion
Coronavirus vaccine with CpG (VLA2001) in healthy adults aged 18 to 55:
a randomised phase 1 /2 clinical trial. medRxiv 2021 [Preprint]. [DOI:
10.1101/2021.08.13.21262021]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1101/2021.08.13.21262021</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Li 2021b</Title>
<Reference>
<Citation>Li J, Hui A, Zhang X, Yang Y, Tang R, Ye H, et al. Safety and
immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and
older Chinese adults: a randomized, placebo-controlled, double-blind
phase 1 study. Nature Medicine 2021;27(6):1062-70.</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">33888900</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Li 2021c</Title>
<Reference>
<Citation>Li M, Yang J, Wang L, Wu Q, Wu Z, Zheng W, et al. A booster dose
is immunogenic and will be needed for older adults who have completed
two doses vaccination with CoronaVac: a randomized, double-blind,
placebo-controlled, phase 1/2 clinical trial. medRxiv 2021 [Preprint].
[DOI: 10.1101/2021.08.03.21261544]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1101/2021.08.03.21261544</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Liu 2021</Title>
<Reference>
<Citation>Liu X, Shaw RH, Stuart AS, Greenland M, Dinesh T,
Provstgaard-Morys S, et al. Safety and immunogenicity report from the
com-COV study – a single-blind randomised non-inferiority trial
comparing heterologous and homologous prime-boost schedules with an
adenoviral vectored and mRNA COVID-19 vaccine. SSRN 2021 [Preprint].</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8346248</ArticleId>
<ArticleId IdType="pubmed">34370971</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Low 2021</Title>
<Reference>
<Citation>Low JG, Alwis R, Chen S, Kalimuddin S, Leong YA, Mah TK, et al. A
phase 1/2 randomized, double-blinded, placebo controlled ascending dose
trial to assess the safety, tolerability and immunogenicity of ARCT-021
in healthy adults. medRxiv 2021 [Preprint]. [DOI:
10.1101/2021.07.01.21259831]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1101/2021.07.01.21259831</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Lv 2021</Title>
<Reference>
<Citation>Lv M, Luo X, Shen Q, Lei R, Liu X, Liu E, et al. Safety,
immunogenicity, and efficacy of COVID-19 vaccines in children and
adolescents: a systematic review. Vaccines 2021;9(10):1102.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8539812</ArticleId>
<ArticleId IdType="pubmed">34696210</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Madhi 2021</Title>
<Reference>
<Citation>Madhi SA, Koen AL, Fairlie L, Cutland CL, Baillie V, Padayachee
SD, et al. ChAdOx1 nCoV-19 (AZD1222) vaccine in people living with and
without HIV. Research Square 2021 [Preprint]. [DOI:
10.21203/rs.3.rs-322470/v1]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.21203/rs.3.rs-322470/v1</ArticleId>
<ArticleId IdType="pmc">PMC8372504</ArticleId>
<ArticleId IdType="pubmed">34416193</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Makris 2021</Title>
<Reference>
<Citation>Makris M, Pavord S, Lester W, Scully M, Hunt B. Vaccine-induced
immune thrombocytopenia and thrombosis (VITT). Research and Practice in
Thrombosis and Haemostasis 2021;5(5):e12529.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8178610</ArticleId>
<ArticleId IdType="pubmed">34136745</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Mammen 2021</Title>
<Reference>
<Citation>Mammen MP Jr, Tebas P, Agnes J, Giffear M, Kraynyak KA, Blackwood
E, et al. Safety and immunogenicity of INO-4800 DNA vaccine against
SARS-CoV-2: a preliminary report of a randomized, blinded,
placebo-controlled, Phase 2 clinical trial in adults at high risk of
viral exposure. medRxiv 2021 [Preprint]. [DOI:
10.1101/2021.05.07.21256652]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1101/2021.05.07.21256652</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Marshall 2020</Title>
<Reference>
<Citation>Marshall JC, Murthy S, Diaz J, Adhikari NK, Angus DC, Arabi YM, et
al. A minimal common outcome measure set for COVID-19 clinical research.
Lancet Infectious Diseases 2020;20(8):e192-7.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC7292605</ArticleId>
<ArticleId IdType="pubmed">32539990</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Mavridis 2014</Title>
<Reference>
<Citation>Mavridis D, Welton NJ, Sutton A, Salanti G. A selection model for
accounting for publication bias in a full network meta-analysis.
Statistics in Medicine 2014;33(30):5399-412.</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25316006</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Meng 2021b</Title>
<Reference>
<Citation>Meng FY, Gao F, Jia SY, Wu XH, Li JX, Guo XL, et al. Safety and
immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy
population aged 18 years or older: two single-center, randomised,
double-blind, placebo-controlled, phase 1 and phase 2 trials. Signal
Transduction and Targeted Therapy 2021;6(1):271.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8281021</ArticleId>
<ArticleId IdType="pubmed">34267185</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Mortola 2004</Title>
<Reference>
<Citation>Mortola E, Roy P. Efficient assembly and release of SARS
coronavirus-like particles by a heterologous expression system. FEBS
Letters 2004;576(1-2):174-8.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC7126153</ArticleId>
<ArticleId IdType="pubmed">15474033</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Mulligan 2020</Title>
<Reference>
<Citation>Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S,
et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.
Nature 2020;586(7830):589-93.</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32785213</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Nguyen 2021</Title>
<Reference>
<Citation>Nguyen TP, Do Q, Phan LT, Dinh DV, Khong H, Hoang LV, et al.
Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike
protein vaccine. medRxiv 2021 [Preprint]. [DOI:
10.1101/2021.07.22.21260942]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1101/2021.07.22.21260942</ArticleId>
<ArticleId IdType="pmc">PMC9108376</ArticleId>
<ArticleId IdType="pubmed">35602004</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Nikolakopoulou 2020</Title>
<Reference>
<Citation>Nikolakopoulou A, Higgins JP, Papakonstantinou T, Chaimani A, Del
Giovane C, Egger M, et al. CINeMA: an approach for assessing confidence
in the results of a network meta-analysis. PLOS Medicine
2020;17 (4):e1003082.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC7122720</ArticleId>
<ArticleId IdType="pubmed">32243458</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Oikonomidi 2020</Title>
<Reference>
<Citation>Oikonomidi T, Boutron I, Pierre O, Cabanac G, Ravaud P, COVID-19
NMA Consortium. Changes in evidence for studies assessing interventions
for COVID-19 reported in preprints: meta-research study. BMC Medicine
2020;18(1):402.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC7745199</ArticleId>
<ArticleId IdType="pubmed">33334338</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Ostrowski 2021</Title>
<Reference>
<Citation>Ostrowski SR, Søgaard OS, Tolstrup M, Stærke NB,
Lundgren J, Østergaard L, et al. Inflammation and platelet
activation after COVID-19 vaccines – possible mechanisms behind
vaccine-induced immune thrombocytopenia and thrombosis. Frontiers in
Immunology 2021;12:779453.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8649717</ArticleId>
<ArticleId IdType="pubmed">34887867</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Ouzzani 2016</Title>
<Reference>
<Citation>Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyanv –
a web and mobile app for systematic reviews. Systematic Reviews
2016;5(1):210.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC5139140</ArticleId>
<ArticleId IdType="pubmed">27919275</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Oxford Vaccine Group 2020</Title>
<Reference>
<Citation>Oxford Vaccine Group. Vaccine Knowledge Project: independent
information about vaccines and infectious diseases. vk.ovg.ox.ac.uk/vk
(accessed prior to 1 November 2022).</Citation>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Page 2021</Title>
<Reference>
<Citation>Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow
CD, et al. The PRISMA 2020 statement: an updated guideline for reporting
systematic reviews. BMJ 2021;372:n71.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8005924</ArticleId>
<ArticleId IdType="pubmed">33782057</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Pajon 2021</Title>
<Reference>
<Citation>Pajon R, Paila YD, Girard B, Dixon G, Kacena K, Baden LR, et al.
Initial analysis of viral dynamics and circulating viral variants during
the mRNA-1273 Phase 3 COVE trial. medRxiv 2021 [Preprint]. [DOI:
10.1101/2021.09.28.21264252]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1101/2021.09.28.21264252</ArticleId>
<ArticleId IdType="pmc">PMC9018421</ArticleId>
<ArticleId IdType="pubmed">35145311</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Pan 2021a</Title>
<Reference>
<Citation>Pan HX, Liu JK, Huang BY, Li GF, Chang XY, Liu YF, et al.
Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine (KCONVAC)
in healthy adults: two randomized, double-blind, and placebo-controlled
Phase 1/2 clinical trials. medRxiv 2021 [Preprint]. [DOI:
10.1101/2021.04.07.21253850]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1101/2021.04.07.21253850</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Pan 2021b</Title>
<Reference>
<Citation>Pan HX, Wu QH, Zeng G, Yang J, Jiang DY, Deng XW,  et al.
Immunogenicity and safety of a third dose, and immune persistence of
CoronaVac vaccine in healthy adults aged 18–59 years: interim
results from a double-blind, randomized, placebo-controlled phase 2
clinical trial. medRxiv 2021 [Preprint]. [DOI:
10.1101/2021.07.23.21261026]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1101/2021.07.23.21261026</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Pérez‐Rodríguez 2021</Title>
<Reference>
<Citation>Pérez-Rodríguez S, la Caridad
Rodríguez-González M, Ochoa-Azze R, Climent-Ruiz Y, Alberto
González-Delgado C, Paredes-Moreno B, et al. A randomized,
double-blind phase I clinical trial of two recombinant dimeric RBD
COVID-19 vaccine candidates: safety, reactogenicity and immunogenicity.
medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.10.04.21264522]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1101/2021.10.04.21264522</ArticleId>
<ArticleId IdType="pmc">PMC8823954</ArticleId>
<ArticleId IdType="pubmed">35164986</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Pitisuttithum 2021</Title>
<Reference>
<Citation>Pitisuttithum P, Luvira V, Lawpoolsri S, Muangnoicharoen S,
Kamolratanakul S, Sivakorn C, et al. Safety and immunogenicity of an
inactivated recombinant Newcastle disease virus vaccine expressing
SARS-CoV-2 spike: interim results of a randomised, placebo-controlled,
Phase 1/2 trial. medRxiv 2021 [Preprint]. [DOI:
10.1101/2021.09.17.21263758]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1101/2021.09.17.21263758</ArticleId>
<ArticleId IdType="pmc">PMC8903824</ArticleId>
<ArticleId IdType="pubmed">35284808</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Polack 2020</Title>
<Reference>
<Citation>Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S,
et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New
England Journal of Medicine 2020;383(27):2603-15.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC7745181</ArticleId>
<ArticleId IdType="pubmed">33301246</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Pollard 2021</Title>
<Reference>
<Citation>Pollard AJ, Bijker EM. A guide to vaccinology: from basic
principles to new developments. Nature Reviews Immunology
2021;21(2):83-100.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC7754704</ArticleId>
<ArticleId IdType="pubmed">33353987</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Pu 2021</Title>
<Reference>
<Citation>Pu J, Yu Q, Yin Z, Zhang Y, Li X, Yin Q, et al. The safety and
immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults
aged 18–59 years: a phase I randomized, double-blinded,
controlled trial. Vaccine 2021;39(20):2746-54.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8040531</ArticleId>
<ArticleId IdType="pubmed">33875266</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Qiao 2020</Title>
<Reference>
<Citation>Qiao J. What are the risks of COVID-19 infection in pregnant
women? Lancet 2020;395(10226):760-2.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC7158939</ArticleId>
<ArticleId IdType="pubmed">32151334</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Ramasamy 2020</Title>
<Reference>
<Citation>Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM,
Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine
administered in a prime-boost regimen in young and old adults (COV002):
a single-blind, randomized, controlled, phase 2/3 trial. Lancet
2020;396(10267):1979-93.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC7674972</ArticleId>
<ArticleId IdType="pubmed">33220855</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Richmond 2021</Title>
<Reference>
<Citation>Richmond P, Hatchuel L, Dong M, Ma B, Hu B, Smolenov I, et al.
Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit
vaccine candidate for COVID-19 in healthy adults: a phase 1, randomized,
double-blind, placebo-controlled trial. Lancet 2021;397(10275):682-94.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC7906655</ArticleId>
<ArticleId IdType="pubmed">33524311</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Riley 2011</Title>
<Reference>
<Citation>Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects
meta-analyses. BMJ 2011;342:d549.</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21310794</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Rizk 2021</Title>
<Reference>
<Citation>Rizk JG, Gupta A, Sardar P, Henry BM, Lewin JC, Lippi G, et al.
Clinical characteristics and pharmacological management of COVID-19
vaccine-induced immune thrombotic thrombocytopenia with cerebral venous
sinus thrombosis: a review. JAMA Cardiology 2021;6(12):1451-60.</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">34374713</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Roozen 2021</Title>
<Reference>
<Citation>Roozen GV, Prins ML, Binnendijk R, den Hartog G, Kuiper VP, Prins
C, et al. Tolerability, safety and immunogenicity of intradermal
delivery of a fractional dose mRNA-1273 SARS-CoV-2 vaccine in healthy
adults as a dose sparing strategy. medRxiv 2021 [Preprint]. [DOI:
10.1101/2021.07.27.21261116]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1101/2021.07.27.21261116</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Roper 2009</Title>
<Reference>
<Citation>Roper RL, Rehm KE. SARS vaccines: where are we? Expert Review of
Vaccines 2009;8(7):887-98.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC7105754</ArticleId>
<ArticleId IdType="pubmed">19538115</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Rotshild 2021</Title>
<Reference>
<Citation>Rotshild V, Hirsh-Raccah B, Miskin I, Muszkat M, Matok I.
Comparing the clinical efficacy of COVID-19 vaccines: a systematic
review and network meta-analysis. Scientific Reports 2021;11(1):22777.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8611039</ArticleId>
<ArticleId IdType="pubmed">34815503</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Rubin 2013</Title>
<Reference>
<Citation>Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et
al. 2013 IDSA clinical practice guideline for vaccination of the
immunocompromized host. Clinical Infectious Diseases
2013;58(3):e44-e100.</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24311479</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Rucker 2013</Title>
<Reference>
<Citation>Rucker G, Schwarzer G, Rücker G, Schwarzer G, Krahn U,
König J. Network meta-analysis using frequentist methods –
package netmeta. cran.r–project.org (accessed prior to 1 November
2022).</Citation>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Ryzhikov 2021</Title>
<Reference>
<Citation>Ryzhikov AB, Ryzhikov ЕА, Bogryantseva MP, Usova SV,
Danilenko ED, Nechaeva EA, et al. A single blind, placebo-controlled
randomized study of the safety, reactogenicity and immunogenicity of the
"EpiVacCorona" vaccine for the prevention of COVID-19. Russian Journal
of Infection and Immunity 2021;11(2):283-96.</Citation>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Sadoff 2020c</Title>
<Reference>
<Citation>Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, Groot AM,
et al. Safety and immunogenicity of the Ad26. COV2. S COVID-19 vaccine
candidate: interim results of a phase 1/2a, double-blind, randomized,
placebo-controlled trial. MedRxiv 2020 [Preprint].</Citation>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Salanti 2011</Title>
<Reference>
<Citation>Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical
summaries for presenting results from multiple-treatment meta-analysis:
an overview and tutorial. Journal of Clinical Epidemiology
2011;64(2):163-7.</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20688472</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Schünemann 2021</Title>
<Reference>
<Citation>Schünemann HJ, Higgins JP, Vist GE, Glasziou P, Akl EA,
Skoetz N, et al. Chapter 14: Completing 'Summary of findings' tables and
grading the certainty of the evidence. In: Higgins JP, Thomas J,
Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane
Handbook for Systematic Reviews of Interventions Version 6.2 (updated
February 2021). Cochrane, 2021. Available from
training.cochrane.org/handbook/archive/v6.2.</Citation>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Sharifian‐Dorche 2021</Title>
<Reference>
<Citation>Sharifian-Dorche M, Bahmanyar M, Sharifian-Dorche A, Mohammadi P,
Nomovi M, Mowla A. Vaccine-induced immune thrombotic thrombocytopenia
and cerebral venous sinus thrombosis post COVID-19 vaccination; a
systematic review. Journal of the Neurological Sciences 2021;428:117607.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8330139</ArticleId>
<ArticleId IdType="pubmed">34365148</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Shinde 2021</Title>
<Reference>
<Citation>Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L, et
al, for the 2019nCoV-501 Study Group. Preliminary efficacy of the
NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. medRxiv 2021
[Preprint].</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8091623</ArticleId>
<ArticleId IdType="pubmed">33951374</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Shu 2021</Title>
<Reference>
<Citation>Shu YJ, He JF, Pei RJ, He P, Huang ZH, Chen SM, et al.
Immunogenicity and safety of a recombinant fusion protein vaccine (V-01)
against coronavirus disease 2019 in healthy adults: a randomized,
double-blind, placebo-controlled, phase II trial. Chinese Medical
Journal 2021;134(16):1967-76.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8382383</ArticleId>
<ArticleId IdType="pubmed">34310400</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Sridhar 2021</Title>
<Reference>
<Citation>Sridhar S, Joaquin A, Bonaparte MI, Bueso A, Chabanon AL, Chen A,
et al. Safety and immunogenicity of a SARS-CoV-2 recombinant protein
vaccine with AS03 adjuvant in healthy adults: interim findings from a
phase 2, randomised, dose-finding, multi-centre study. medRxiv 2021
[Preprint]. [DOI: 10.1101/2021.10.08.21264302]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1101/2021.10.08.21264302</ArticleId>
<ArticleId IdType="pmc">PMC8789245</ArticleId>
<ArticleId IdType="pubmed">35090638</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Stephenson 2021</Title>
<Reference>
<Citation>Stephenson KE, Le Gars M, Sadoff J, Groot AM, Heerwegh D, Truyers
C, et al. Immunogenicity of the Ad26.COV2.S vaccine for COVID-19. JAMA
2021;325(15):1535-44.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC7953339</ArticleId>
<ArticleId IdType="pubmed">33704352</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Sterne 2019</Title>
<Reference>
<Citation>Sterne JA, Savović J, Page MJ, Elbers RG, Blencowe NS,
Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in
randomized trials. BMJ 2019;366:l4898.</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">31462531</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Thomas 2021</Title>
<Reference>
<Citation>Thomas SJ, Moreira ED, Kitchin N, Absalon J, Gurtman A, Lockhart
S, et al. Six month safety and efficacy of the BNT162b2 Mrna Covid-19
vaccine. medRxiv 2021 [Preprint].</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8461570</ArticleId>
<ArticleId IdType="pubmed">34525277</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Turner 2012</Title>
<Reference>
<Citation>Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JP. Predicting
the extent of heterogeneity in meta-analysis, using empirical data from
the Cochrane Database of Systematic Reviews. International Journal of
Epidemiology 2012;41(3):818-27.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC3396310</ArticleId>
<ArticleId IdType="pubmed">22461129</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>van Riel 2020</Title>
<Reference>
<Citation>Riel D, Wit E. Next-generation vaccine platforms for COVID-19.
Nature Materials 2020;19(8):810-2.</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32704139</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Viechtbauer 2010</Title>
<Reference>
<Citation>Viechtbauer W. Conducting meta-analyses in R with the metafor
package. Journal of Statistical Software 2010;36(3):1-48.</Citation>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Voysey 2021b</Title>
<Reference>
<Citation>Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley
PK, et al. Single-dose administration and the influence of the timing of
the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19
(AZD1222) vaccine: a pooled analysis of four randomized trials. Lancet
2021;397(10277):881-91.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC7894131</ArticleId>
<ArticleId IdType="pubmed">33617777</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Walsh 2021</Title>
<Reference>
<Citation>Walsh EE, Frenck R, Falsey AR, Kitchin N, Absalon J, Gurtman A, et
al. RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy
study. medRxiv 2021 [Preprint].</Citation>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Ward 2021b</Title>
<Reference>
<Citation>Ward BJ, Gobeil P, Séguin A, Atkins J, Boulay I, Charbonneau
PY, et al. Phase 1 randomized trial of a plant-derived virus-like
particle vaccine for COVID-19. Nature Medicine 2021;27(6):1071-8.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8205852</ArticleId>
<ArticleId IdType="pubmed">34007070</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>White 2008</Title>
<Reference>
<Citation>White IR, Higgins JP, Wood AM. Allowing for uncertainty due to
missing data in meta-analysis – part 1: two-stage methods.
Statistics in Medicine 2008;27(5):711-27.</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17703496</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>WHO 2020a</Title>
<Reference>
<Citation>World Health Organization. Coronavirus disease 2019 (COVID-19).
Situation report – 51. apps.who.int/iris/handle/10665/331475
(accessed prior to 1 November 2022).</Citation>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>WHO 2020b</Title>
<Reference>
<Citation>World Health Organization. Considerations for evaluation of
COVID19 vaccines. Points to consider for manufacturers of COVID-19
vaccines. Version 24 September 2020.
www.who.int/docs/default-source/in-vitro-diagnostics/covid19/who-evaluation-covid-vaccine-w-lines.pdf?sfvrsn=701d3a65_2
(accessed prior to 1 November 2022).</Citation>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>WHO 2020c</Title>
<Reference>
<Citation>World Health Organization. WHO target product profiles for
COVID-19 vaccines. Version 3 – 29 April 2020.
www.who.int/docs/default-source/blue-print/who-target-product-profiles-for-covid-19-vaccines.pdf
(accessed prior to 1 November 2022).</Citation>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>WHO 2022a</Title>
<Reference>
<Citation>World Health Organization. Tracking SARS-CoV-2 variants.
www.who.int/activities/tracking-SARS-CoV-2-variants (accessed prior to 1
November 2022).</Citation>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>WHO 2022b</Title>
<Reference>
<Citation>World Health Organization. COVID-19 vaccine tracker and landscape.
www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
(accessed prior to 1 November 2022).</Citation>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>WHO Ad Hoc Expert Group 2021</Title>
<Reference>
<Citation>WHO Ad Hoc Expert Group on the Next Steps for Covid-19 Vaccine
Evaluation. Placebo-controlled trials of covid-19 vaccines – why
we still need them. New England Journal of Medicine 2021;384:e2. [DOI:
10.1056/NEJMp2033538]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1056/NEJMp2033538</ArticleId>
<ArticleId IdType="pubmed">33264543</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Worldometer 2022</Title>
<Reference>
<Citation>Worldometer. COVID-19 coronavirus pandemic.
www.worldometers.info/coronavirus/#countries (accessed prior to 1
November 2022).</Citation>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Wu 2021c</Title>
<Reference>
<Citation>Wu S, Huang J, Zhang Z, Wu J, Zhang J, Hu H, et al. Safety,
tolerability, and immunogenicity of an aerosolised adenovirus type-5
vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report
of an open-label and randomised phase 1 clinical trial. Lancet
Infectious Diseases 2021;21(12):1654-64.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8313090</ArticleId>
<ArticleId IdType="pubmed">34324836</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Xia 2020</Title>
<Reference>
<Citation>Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, et al. Effect of
an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity
outcomes: interim analysis of 2 randomized clinical trials. JAMA
2020;324(10):951-60.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC7426884</ArticleId>
<ArticleId IdType="pubmed">32789505</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Yang 2021</Title>
<Reference>
<Citation>Yang S, Li Y, Dai L, Wang J, He P, Li C, et al. Safety and
immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein
subunit vaccine (ZF2001) against COVID-19 in adults: two randomized,
double-blind, placebo-controlled, phase 1 and 2 trials. Lancet
Infectious Diseases 2021;21(8):1107-19.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC7990482</ArticleId>
<ArticleId IdType="pubmed">33773111</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Yepes‐Nuñez 2019</Title>
<Reference>
<Citation>Yepes-Nuñez JJ, Li SA, Guyatt G, Jack SM, Brozek JL, Beyene
J, et al. Development of the summary of findings table for network
meta-analysis. Journal of Clinical Epidemiology 2019;115:1-13.</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">31055177</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Zakarya 2021</Title>
<Reference>
<Citation>Zakarya K, Kutumbetov L, Orynbayev M, Abduraimov Y, Sultankulova
K, Kassenov M, et al. A single-centre, randomized, single-blind,
placebo-controlled phase 1 and an open-label phase 2 clinical trials
with a 6 months follow-up in Kazakhstan. EClinicalMedicine
2021;39:101078.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8363482</ArticleId>
<ArticleId IdType="pubmed">34414368</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Zeng 2021a</Title>
<Reference>
<Citation>Zeng L, Brignardello-Petersen R, Hultcrantz M, Siemieniuk RA,
Santesso N, Traversy G, et al. GRADE guidelines 32: GRADE offers
guidance on choosing targets of GRADE certainty of evidence ratings.
Journal of Clinical Epidemiology 2021;137:163-75.</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">33857619</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Zeng 2021b</Title>
<Reference>
<Citation>Zeng B, Gao L, Zhou Q, Yu K, Sun F. Effectiveness of COVID-19
vaccines against SARS-CoV-2 variants of concern: a systematic review and
meta-analysis. medRxiv 2021 [Preprint]. [DOI:
10.1101/2021.09.23.21264048]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1101/2021.09.23.21264048</ArticleId>
<ArticleId IdType="pmc">PMC9126103</ArticleId>
<ArticleId IdType="pubmed">35606843</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Zhang 2021b</Title>
<Reference>
<Citation>Zhang J, Hu Z, He J, Liao Y, Li Y, Pei R, et al. Safety and
immunogenicity of a recombinant interferon-armed RBD dimer vaccine
(V-01) for COVID-19 in healthy adults: a randomized, double-blind,
placebo-controlled, Phase I trial. Emerging Microbes & Infections
2021;10(1):1589-97.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8366678</ArticleId>
<ArticleId IdType="pubmed">34197281</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Zhu 2020</Title>
<Reference>
<Citation>Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, et al.
Immunogenicity and safety of a recombinant adenovirus type-5-vectored
COVID-19 vaccine in healthy adults aged 18 years or older: a randomized,
double-blind, placebo-controlled, phase 2 trial. Lancet
2020;396(10249):479-88.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC7836858</ArticleId>
<ArticleId IdType="pubmed">32702299</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Zhu 2021a</Title>
<Reference>
<Citation>Zhu F, Jin P, Zhu T, Wang W, Ye H, Pan H, et al. Safety and
immunogenicity of a recombinant adenovirus type-5-vectored COVID-19
vaccine with a homologous prime-boost regimen in healthy participants
aged 6 years and above: a randomized, double-blind, placebo-controlled,
phase 2b trial. Clinical Infectious Diseases 2022;75(1):e783-91. [DOI:
10.1093/cid/ciab845]</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1093/cid/ciab845</ArticleId>
<ArticleId IdType="pmc">PMC8522421</ArticleId>
<ArticleId IdType="pubmed">34551104</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList>
<Title>Zhu 2022</Title>
<Reference>
<Citation>Zhu F, Jin P, Zhu T, Wang W, Ye H, Pan H, et al. Safety and
immunogenicity of a recombinant adenovirus type-5-vectored COVID-19
vaccine with a homologous prime-boost regimen in healthy participants
aged 6 years and above: a randomized, double-blind, placebo-controlled,
phase 2b trial. Clinical Infectious Diseases 2022;75(1):e783-91.</Citation>
<ArticleIdList>
<ArticleId IdType="pmc">PMC8522421</ArticleId>
<ArticleId IdType="pubmed">34551104</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</ReferenceList>
<ReferenceList>
<Title>References to other published versions of this review</Title>
<ReferenceList>
<Title>Grana 2021</Title>
<Reference>
<Citation>Grana C, Ghosn L, Boutron I. Efficacy and safety of COVID-19
vaccines: a systematic review and meta-analysis. PROSPERO 2021
CRD42021271897.
www.crd.york.ac.uk/prospero/display_record.php?RecordID=271897 (accessed
prior to 1 November 2022).</Citation>
</Reference>
</ReferenceList>
</ReferenceList>
</PubmedData>
</PubmedArticle>
</PubmedArticleSet> |